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CHAPTER I 
 
Introduction 
 
Gram negative-bacteria  
Bacteria can be divided into Gram-negative and Gram-positive groups based on 
their ability to be stained by crystal violet or a counterstain, like safranin (1).  Subsequent to 
this functional classification, it has been shown that bacteria that stain with crystal violet 
contain a single membrane and a thick peptidoglycan layer.  Conversely, Gram-negative 
bacteria have a characteristic double membrane composed of an inner membrane, a thin 
peptidoglycan layer within the intervening (periplasmic) space, and an outer membrane. 
Bacterial infection remains a major cause of death worldwide (2) with Gram-
negative bacteria predicted to become the major cause of death from bacterial infection in 
the near future (3).  Gram-negative bacteria are significant public health threats, 
responsible for pneumonia, blood stream infections, wound or surgical site infections, and 
meningitis (4).  Additionally, antibiotic resistance among Gram-negative bacteria is a 
significant and growing concern (4-6).  The additional membrane renders Gram-negative 
bacteria inherently less sensitive to antibiotics than Gram-positives (4), and the prevalence 
of acquired resistance multiple drugs (multidrug resistance, MDR) is increasing, especially 
to frequently used antibiotics (4-6).  The Centers for Disease Control and Prevention (CDC) 
indicate that there are more than two million people infected every year, and at least 
23,000 deaths result from antibiotic resistant infections per year in the United States (5).  
Recent data implicate gram-negative bacteria in over 30% of nosocomial infections, 
including 47% of pneumonia cases, and 45% of urinary tract infections (UTIs) alone (7).  In 
U.S. intensive care units, gram-negative bacteria account for nearly 70% pneumonia and 
UTIs (8).  Domestic healthcare costs associated with and resulting from antibiotic 
resistance are estimated to be at least $20 billion per year (9,10). 
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Major Gram-Negative pathogens and antibiotic resistance threats 
Aside from the double membrane, gram-negative bacteria have acquired 
specialized features that allow for increased antibiotic resistance.  These traits include 
acquisition of novel proteins (via horizontal gene transfer) and adaptations in the regulation 
of existing proteins (4).  Examples include: the reduced expression of porins, which reduce 
drug influx; acquisition or enhanced expression of efflux pumps; acquisition of β-
lactamases and other antibiotic detoxifying enzymes; alteration of bacterial ribosomes such 
that ribosome-targeted antibiotics are ineffective; point mutations in antibiotic targets that 
reduce antibiotic binding; acquisition of alternative metabolic enzymes bypassing 
metabolism-targeted antibiotics; and mutations in the lipopolysaccharide.  Examples of 
these resistance strategies are shown in Figure 1-1 (4,6). 
The 2013 CDC report on antibiotic resistance lists carbapenem-resistant 
Enterobacteriaceae (encompassing Salmonella, Escherichia, Yersinia, Klebsiella, Shigella, 
etc.) and drug-resistant Neisseria gonorrhoeae as urgent threats to human health (5).  
These bacteria are poised to rapidly become global threats unless action is taken in the 
sphere of public health to alter their prevalence.  The CDC’s recent analysis also highlights 
the following gram-negative bacteria as the most serious threats: multidrug-resistant 
Acinetobacter, drug-resistant Campylobacter, extended spectrum β-lactamase producing 
Enterobacteriaceae (which includes Salmonella, Escherichia coli, Yersinia pestis, 
Klebsiella, Shigella, Proteus, Enterobacter, Serratia, and Citrobacter), multidrug-resistant 
Pseudomonas aeruginosa, drug-resistant non-typhoidal Salmonella, drug resistant 
Salmonella typhi, and drug resistant Shigella spp. (5).  Table 1-1 summarizes the number 
of infections and deaths caused by these gram-negative bacteria.  From these data, it is 
clear that the most serious gram-negative infections are health-care associated from 
Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter. 
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Figure 1-1: Mechanisms of antibiotic resistance in gram-negative bacteria. (A) 
Ribosomal mutations/modification; (B) Bypass targets; (C) mutations in lipopolysaccharide 
structure; (D) loss of porins; (E) β-lactamases in periplasm; (F) Over-expression of 
transmembrane efflux pumps; (G) Antibiotic-modifying enzymes; (H) and targeted 
mutations. Adapted from Peleg et al. 2010 (4). 
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Table 1-1: Estimated morbidity and mortality from antibiotic-resistance. Adapted from 
Center for Disease Control and Prevention’s ‘Antibiotic Resistance Threats in the United 
States, 2013.’ (5) 
Antibiotic 
Resistant 
Gram-
negative 
Bacteria 
Infections 
Included in 
Case/Death 
Estimates 
Infections Not 
Included 
Antibiotic 
Resistance 
Estimated 
Annual 
Number of 
Cases 
Estimated 
Annual 
Number of 
Deaths 
Carbapenem-
resistant 
Enterobacteri
aceae (CRE) 
Healthcare-
associated 
infections 
(HAIs) caused 
by Klebsiella 
and E. coli 
with onset in 
hospitalized 
patients 
Infections 
occurring outside 
of acute care 
hospitals (e.g., 
nursing homes) 
 
Infections acquired 
in acute care 
hospitals but not 
diagnosed until 
after discharge 
 
Infections caused 
by 
Enterobacteriacea
e other than 
Klebsiella and E. 
coli (e.g., 
Enterobacter spp.) 
Some of these 
bacteria are 
resistant to: 
 
- Nearly all 
antibiotics, 
including 
carbapenems 
9,300 610 
Drug-resistant 
Neisseria 
gonorrhoeae 
(any drug) 
All infections Not applicable Strains show 
resistance to: 
 
- Cefixime (oral 
cephalosporin 
- Ceftriaxone 
(injectable 
cephalosporin) 
- Azithromycin 
- Tetracycline 
 
246,000 < 5 
Multidrug-
resistant 
Acinetobacter 
(three or more 
drug classes) 
HAIs with 
onset in 
hospitalized 
patients 
Infections 
occurring outside 
of acute care 
hospitals (e.g., 
nursing homes) 
 
Infections acquired 
in acute care 
hospitals but not 
diagnosed until 
after discharge 
 
 
Some strains are 
resistant to: 
- All antibiotics 
including 
carbapenems 
7,300 500 
Drug-resistant 
Campylobact
er 
(azithromycin 
or 
ciprofloxacin) 
All infections Not applicable Strains show 
resistance to: 
- Ciprofloxacin 
- Azithromycin 
310,000 220 
Extended-
spectrum β-
lactamase 
producing 
Enterobacteri
aceae 
(ESBLs) 
HAIs caused 
by Klebsiella 
and E. coli 
with onset in 
hospitalized 
patients 
Infections 
occurring outside 
of acute care 
hospitals (e.g., 
nursing homes) 
 
Infections acquired 
Some strains are 
resistant to nearly 
all: 
- Penicillins 
- Cephalosporins 
26,000 1,700 
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in acute care 
hospitals but not 
diagnosed until 
after discharge 
 
Infections caused 
by 
Enterobacteriacea
e other than 
Klebsiella and E. 
coli (e.g., 
Enterobacter spp.) 
Multidrug-
resistant 
Pseudomona
s aeruginosa 
(three or more 
drug classes) 
HAIs with 
onset in 
hospitalized 
patients 
Infections 
occurring outside 
of acute care 
hospitals (e.g., 
nursing homes) 
 
Infections acquired 
in acute care 
hospitals but not 
diagnosed until 
after discharge 
 
Some strains 
have been found 
to be resistant to: 
- Most antibiotics 
- Aminoglycosides 
- Cephalosporins 
- 
Fluoroquinolones 
- Carbapenems 
6,700 440 
Drug-resistant 
non-typhoidal 
Salmonella 
(ceftriaxone, 
ciprofloxacin, 
or 5 or more 
drug classes) 
All infections Not applicable Strains are 
showing 
resistance to: 
- Ceftriaxone 
- Ciprofloxacin 
- Multiple classes 
of drugs 
100,000 40 
Drug-resistant 
Salmonella 
Typhi 
(ciprofloxacin) 
All infections Not applicable Showing 
resistance to: 
- Ceftriaxone 
- Azithromycin 
- Ciprofloxacin 
(resistance is so 
common that this 
drug is not 
routinely used) 
3,800 < 5 
Drug-resistant 
Shigella 
(azithromycin 
ciprofloxacin) 
All infections Not applicable Strains are 
resistant to: 
- Ampicillin (high 
resistance levels) 
- Trimethoprim-
sulfamethoxazole 
(high resistance 
levels) 
- Ciprofloxacin 
- Azithromycin 
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Secretion systems of Gram-negative bacteria 
Bacterial infection requires the establishment of hospitable niches for replication 
and dissemination.  Many bacteria secrete protein effectors to aid in infection.  Protein 
secretion is essential for both prokaryotes and eukaryotes, as a key mechanism through 
which they interact with and adapt to their environments.  In particular, bacteria utilize 
secretion systems to make their environment more hospitable.  Secreted proteases are 
used to obtain nutrients, and toxins expand the pathogen’s niche by targeting competing 
bacteria or a eukaryotic host.  Infection by Gram-negative bacteria involves secretion of 
effector proteins from bacteria into host cells.  These effectors aid infection by blunting host 
defenses and co-opting host process (11-13).  In order to direct secreted effector proteins 
across the inner and outer membranes, gram-negative bacteria utilize specialized secretion 
systems.  There are now, at least, seven known secretion systems that gram negative 
bacteria utilize, named sequentially from the type I secretion system (T1SS) to the type VII 
secretion system (T7SS) (14-18).  Effectors traverse the inner membrane (IM) and outer 
membrane (OM) either by a one-step transport process (T1SS, T3SS, T4SS, T6SS, and 
T7SS) that leads the unfolded substrate into the extracellular space without assistance 
from periplasmic intermediates, or by a two-step process (T2SS, T4SS, T5SS) where 
substrates are transported to the periplasm, where they fold, and are subsequently 
transported across the OM (19-21).  The T2SS, T4SS, and T5SS are dependent on the 
Sec and Tat pathways—the major pathways used to secrete proteins across the inner 
membrane and into the periplasm (19-22). 
 
The Sec Secretion Pathway 
The Sec pathway was originally identified by genetic studies in conditional lethal 
mutants exhibiting secretion defects (23).  The Sec system consists of protein-targeting 
components, a motor protein, and a membrane integrated protein conducting channel (24).  
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The bacterial Sec translocase is composed of a membrane-embedded, protein-conducting 
channel that consists of three integral membrane proteins, SecY, SecE, and Sec G, and a 
peripheral associated ATPase, SecA, that functions as a molecular motor to drive the 
translocation of secretory proteins across the IM (24-26).  In many Gram-negative bacteria, 
secretory proteins are guided to the Sec-translocase by the secretion specific chaperone, 
SecB, that maintains these proteins in a translocation-competent, unfolded state (27).  
Once at the membrane they are translocated by the heterotrimeric protein complex, Sec 
YEG, which is embedded in the IM of gram-negative bacteria (28). 
 
The Twin-Arginine Translocation (Tat) Pathway  
The second general secretion system that translocates proteins across the inner 
membrane is the Twin-Arginine Translocation (Tat) pathway (29,30).  The Tat translocases 
consist of two or three membrane-integrated subunits, (TatA and TatC, or TatA, TatB and 
TatC), which together from a receptor and protein conducting machinery for substrates.  
The Tat system recognizes a conserved amino acid sequence (polar-Arg-Arg-hydrophobic-
hydrophobic) on substrates, and directs proteins displaying this sequence for secretion 
(29).  A key functional difference between the Sec and Tat systems is that many of the Tat 
substrates assemble with cofactors prior to translocation, and are thought to be fully folded 
when secreted (30-32).  Perhaps for this reason, the Tat system is necessary for multiple 
redox pathways (32-35).  Another important difference between the Tat and Sec pathways 
is that unlike the Sec system, which has a specialized ATPase and uses ATP as an energy 
source, the Tat system uses the proton motive force as an energy source. 
 
Type I secretion system 
The T1SS is a Sec/TAT-independent system that consists of a three proteins, 
which assemble into a tunnel-like structure (Figure 1-2) that delivers substrates directly 
	   8	  
from the cytosol to the extracellular space (36,37).  Essential T1SS components include an 
ABC transporter, a membrane fusion protein (MFP), and an outer membrane protein factor 
(OMF) (38).  T1SS substrates contain a secretion sequence located on either the N- or C-
terminus that is recognized by the T1SS (38).  The ABC transporter uses energy released 
from ATP hydrolysis to translocate substrates across the IM (39).  The inner membrane 
anchored MFP forms a conduit between the ABC transporter and the OMF by spanning the 
periplasm and connects ABC transporter to the OMF pore (40).  The OMF protein forms 
the pore on the OM through which, substrates traverse into the extracellular space (38). 
The ABC transporter consists of two transmembrane domains and two nucleotide-
binding domains, which can be independent polypeptides, (41,42).  The transmembrane 
helices form the conduit that substrates use to traverse the IM (43), while the nucleotide 
binding domains supply the energy required for substrate translocation via ATP hydrolysis 
(44).  The nucleotide binding domains face each other in a head-to-tail orientation that 
sandwiches the nucleotide for an efficient transport of the substrate across the ABC 
transporter (39,45,46).  Within T1SS systems, nucleotide-binding domains exhibit high 
sequence conservation, indicating an essential function (38).  Conversely, the 
transmembrane domains are highly variable because these domains are responsible for 
disparate and species-specific substrates binding and transport (38). 
Many T1SS ABC transporters deviate from the previously mentioned classical 
arrangement and have additional domains located on the cytosolic N-terminus of the 
transporter (38).  These T1SS ABC transporter variations are divided into three distinct 
groups.  The first group encompasses C39-containing transporters responsible for the 
secretion of small (<10 kDa) Class II microcins, which exhibit Ca2+-dependent C39 
peptidase-like activity, (common to the papain superfamily) (47-50).  These C39-containing 
transporters recognize double glycine motifs present in Class II microcins, and cleave the 
N-terminal secretion signal l (49,50).  The second group of transporters is the CLD-
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containing ABC transporters.  These transporters structurally resemble C39-containing 
transporters but lack protease activity (51,52).  The CLD-containing transporters are 
responsible for the secretion of hemolysin (36,52).  The third class of ABC transporters 
also contains the ABC/C39-like domains described above; however, their substrates are 
more diverse hydrolytic proteins, including proteases and lipases. 
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Figure 1-2: A model of type I 
secretion system. Type I secretion 
systems are simple, three-part 
systems facilitating the passage of 
proteins of various sizes across the 
cell envelope of Gram-negative 
bacteria.   They consist of an ATP-
binding cassette (ABC) transporter 
or a proton-antiporter, an adaptor 
protein that bridges the inner 
membrane (IM) and outer 
membrane (OM), and an outer 
membrane pore. They secrete 
substrates in a single step without a 
stable periplasmic intermediate.  
Adapted from Fronzes et. al. 2009 
(18). 
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Type II secretion system 
The type II secretion pathway uses a two-step process to secrete folded or 
oligomeric proteins into the extracellular space, where the substrates may be covalently 
bonded to the bacterial cell.  These secreted proteins are often either involved in nutrient 
acquisition, such as hydrolytic enzymes that degrade biopolymers, or are toxins, that 
invade potential hosts (53-57).  T2SS substrates that become chemically linked to the cell 
wall are often adhesins, cytochromes, motility proteins, or involved in biofilm formation (53-
57).  In Chlamydia, the T2SS is used to secrete proteins involved in host glycogen 
degradation (58).  These substrates contain N-terminal signal sequences that target them 
to the Sec or Tat protein export systems.  Substrates exported by the Sec system are 
unfolded until they reach the periplasm where chaperones and the periplasmic 
environment facilitate proper folding before exiting the OM (59-63).  It is clear from genomic 
studies that hundreds of bacterial species contain T2SS proteins in their genomes (64-68). 
The T2SS in Gram-negative bacteria contain between 12 and 16 genes designated 
for the general secretory pathway, which are denoted as gsp (68).  The current model for 
T2S is summarized in Figure 1-3.  In the cytosol, the ATPase GspE couples to the full 
apparatus through interactions with bitopic protein, GspL (69-72).  The first sub-complex is 
the inner membrane platform, composed of five inner membrane proteins (GspC, GspF, 
GspL, and GspM) that form a pilus-like structure that might act as a piston, pushing the 
substrate through a protein complex termed the secretin (71).  The T2SS relies on the Sec 
or Tat systems to deliver substrates to the periplasm, where the T2SS then exports the 
substrate into the extracellular space (73).  The secretin, is a cylindrical GspD oligomer that 
forms a channel for substrates to exit into extracellular environment (74-78).  In the 
periplasm, proteins called pseudopilins are thought to form a piston-like structure (75-82).  
The current model for secreton operation involves a piston like structure and ATP 
hydrolysis (83,84), pumping the substrates into the extracellular space (85-87). 
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Figure 1-3:  Model of secreton assembly and operation of the type II secretion 
system. 1) First, secretin assembles at the OM.  2) The next step is successive 
recruitment of the trans-periplasmic protein GspCP 3) tethering to the inner membrane 
surface.  4) Substrate recognition by the T2SS takes place in the periplasm, which may 
involve a peripheral element of the secreton, GspCP.  5) The substrate transferred to the 
secretin 6) where it contacts the pseudopilus tip complex that is emerging from the inner 
membrane surface.  7) The exoprotein is then released in the extracellular medium through 
the secretin pore.  The secretin and GspCP are shown in blue, the components of the inner 
membrane are shown in green, the pseudopilus and the secreted proteins are shown in 
orange/red and yellow, respectively.  Adapted from Douzi et al. 2012 (19). 
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Type III secretion system 
Research in the late 1980’s and early 1990’s yielded evidence for a third secretory 
system in gram-negative bacteria.  This secretory system, termed the Type III secretion 
system, is often contained in the invasion (inv) gene locus in T3SS-containing bacteria.  
The T3SS is a large syringe-like apparatus (88-92).  This system is sequentially 
constructed from inside the cell, where secreted proteins first extend through the inner 
membrane, then the periplasm, spanning the bacterial outer membrane, and finally forming 
a pore in the host plasma membrane (93).  The base of this complex contains an ATPase 
that generates energy for the secretion system (94-99).  The substrates targeted for 
secretion into host cells are presented to the T3SS apparatus by specific T3S chaperones 
(100-105).  These chaperones bind N-terminal signal sequences, which mark bacterial 
effector proteins for secretion.  Once at the T3SS apparatus, the N-terminus of the effector 
is fed through the syringe and the apparatus unfolds effectors and passes them directly 
through the T3SS needle and into target cells (106,107). 
The T3SS apparatus, shown in Figure 1-4, is built of six main assemblies: the 
export scaffold, the basal body, the needle, the needle tip, the translocon (which is formed 
by a subset of secreted proteins termed translocators), and accessory proteins.  The 
export scaffold consists of an ATPase, a central stalk, a peripheral stalk, a C-ring, a gate, 
gatekeeper, autoprotease, and three inner membrane components (93).  The basal body 
consists of two inner membrane rings, an outer membrane ring, pilotin, and an inner rod 
(108-114).  The needle consists of a multimeric filament, made up of a single, species-
specific protein (115-117).  The translocation tip is comprised of a major and minor subunit 
(118-120).  Accessory proteins include effectors and needle length regulators (121,122). 
There are two models for export scaffold and basal body assembly of the T3SS: 
the Salmonella “inside-out” (123) and Yersinia “outside-in” (124,125) models.  In the 
“inside-out” Salmonella model, the export scaffold initiates assembly at the IM, the general 
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order of assembly is as follows: first, the basal body rings and export scaffold must 
assemble; second, the formation of the inner rod and needle filament; third, the needle tip 
and the translocator major/minor units oligomerize; and finally, the secretion of bacterial 
effectors into the host cell occurs (123).  Once the export apparatus is assembled at the 
IM, the basal body assembles adjacent to the export apparatus inside the cell.  In the 
Yersinia “outside-in” model, the first basal body IM ring and export apparatus assemble in 
parallel.  Next, the second basal body IM ring forms, followed by the final ATPase domain 
and C-ring assembly components.  After the assembly of the export apparatus and basal 
body, the inner rod and hollow needle filament form sequentially. 
Fully assembled T3SSs are capable of secretion, but do not begin secretion until 
an external signal triggers secretion of a protein termed the “gatekeeper” (126-131).  
Before secretion these gatekeepers are localized to the bacterial membrane via 
interactions with other components of the T3SS (109,129,130,132).  These gatekeepers 
have conserved 4-helix bundle domains with the third C-terminal domain (133).  The inner 
rod, needle, and secreted proteins all employ ATP hydrolysis to pump substrates from the 
bacteria to the host (134). 
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Figure 1-4: A model for type III secretion system. Before host engagement gatekeeper-
chaperone-translocator complexes are bound to the apparatus and prevent secretion of 
effectors. Upon binding of the apparatus to target membranes the, gatekeeper and pore 
forming translocators are secreted.  The pore forming translocators assemble within the 
target membrane to form the translocon.  After translocator and gatekeeper secretion, the 
apparatus is able to efficiently secrete effectors, which are secreted through the translocon 
directly into the host cytosol.  Adapted from Archuleta et al. 2014 (in revision). 
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Type IV secretion system 
The T4SS is present in most Gram-negative bacteria, and can be divided into two 
subgroups: the conjugation system and the effector translocation system, which 
translocate DNA and protein respectively into other cells (135).  The conjugation systems 
are responsible for DNA transfer between bacteria, which allows for genetic diversity in, 
and transfer of bacterial antibiotic resistance and bacterial virulence determinants 
(136,137).  The effector secretion system subgroup utilizes the T4SS machinery to deliver 
protein substrates into eukaryotic hosts through a one or two-step process.  In the one-step 
process, the type IV coupling protein (T4CP), a hexameric ATPase, drives protein 
secretion (20).  Whereas the two-step process, substrates are delivered to the periplasm 
by SecYeG machinery, where substrates engage with the T4S machine for translocation 
across the outer membrane (18,20).  Helicobacter pylori, Legionella pneumophila, Brucella 
spp., Bartonella spp., and Rickettsial spp. all utilize the T4SS for infecting their eukaryotic 
hosts (136,138-142). 
The T4SS is composed of four functionally distinct subassemblies.  The first 
(T4CP), provides the energy to drive the substrate out of the cell (143).  Next, the inner 
membrane complex (IMC), transfers substrates across the inner membrane (144).  Then 
an envelope-spanning outer membrane complex (OMC) receives the substrate from the 
IMC and transfers them across the periplasm and outer membrane (20).  Finally, a pilus 
initiates contact with a host cell, and the substrate is pushed into the host cell (145). 
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Figure 1-5: The one and two-step type IV secretion system. In the T4CP-independent 
pathway, The Sec system transfers the substrate from the cytoplasm to the periplasmic 
region of the T4CP.  Once the substrate is transferred to the core/OM channel where it is 
translocated across the outer membrane.  In the T4CP-dependant pathway, the substrates 
dock with the T4CP in the cytosol.  Then the T4CP translocates the substrate across the 
inner membrane into the channel region, in the periplasm.  Finally, the substrate is 
translocated across the OM channel.  Adapted from Christie et al. 2014 (20). 
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Type V secretion system 
The TVSSs includes five subgroups of auto transporters: type Va, type Vb, type 
Vc, type Vd, and type Ve. 
Type Va subgroup is the considered the classical, monomeric auto-transporter 
system.  These autotransporter polypeptides contain all functions needed for translocation 
across both membranes (146,147).  Va autotransporters are synthesized by ribosomes 
attached to the Sec system (148).  As the auto-transporter is threaded through the Sec 
machinery, its N-terminus remains attached to the Sec-system.  In E. coli, chaperones 
keep the autotransporter unfolded in the periplasm (149-152).  This monomeric 
autotransporter is then be inserted into the outer membrane (OM).  Recently, it has been 
shown that β-barrel insertion into the OM requires a set of accessory proteins that form a 
β-barrel assembly complex (153).  An example of one of these assembly complex 
chaperones is the N. meningitides protein BamA.  The BamA complex catalyzes a fast and 
efficient insertion of the autotransporter β-barrel into the OM. 
The T5SS type Vb is a two-partner system (TPS).  In this system, the passenger 
and translocator functions of the autotransporter are located in two separate polypeptide 
chains:  the passenger polypeptide (TpsA), and the β-barrel transport protein (TpsB).  
Typically, each TpsB transporter is dedicated to transporting a single TpsA substrate 
protein (154).  However, there has been one case where a single TpsB transporter 
transports two different passengers, FhaC in Bordetella bronchiseptica (155).  It is 
presumed that this class also contains periplasmic type Va-like chaperones (15). 
The type Vc system is a trimeric autotransporter, where three discrete monomers 
translocate through a single pore, and typically form OM-linked trimeric adhesions (156).  
These proteins contain no enzymatic activity and remain tethered to the cell surface.  
These trimeric autotransporter adhesins (TAAs) have a modular and repetitive architecture.  
The modular arrangement of the TAAs allows pathogens to frequently and easily 
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recombine their adhesins, facilitating adaptation to host environments (157).  As with type 
Va and Vb, type Vc similarly requires periplasmic chaperones to help fold and quickly 
insert into the membrane (15). 
Type Vd systems are autotransporters with patatin-like lipase activity.  The best-
described example of this class is PlpD, from Pseudomonas aeruginosa.  The passenger 
protein’s N-terminus contains four conserved domains necessary for its lipase activity.  
These particular autotransporters contain 16-stranded β-barrels, similar to the type Vb 
system (158). 
The type Ve sub family system is similar to the type Va, the classical 
autotransporters, but is inverted.  In this case,  the N-terminus of the protein encodes the 
β-barrel domain, and the C-terminus encodes the protein substrate component (159). 
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Figure 1-6: Topology models of the five, type V secretion systems. T5SS’s Va-Ve are 
displayed above with the translocation domain displayed in brown, linker/Tps regions in 
light green, passenger domains in dark green, and periplasmic domains in orange.  
Adapted from Leo et al. 2012 (15). 
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Type VI secretion system 
Type VI secretion system (T6SS) is a membrane-puncturing syringe assembly that 
injects effector proteins directly into the host (160-163).  The T6SS is structurally similar to 
the bacteriophage tail and baseplate (164-166).  T6SS can be separated into four 
categories based on their observed functions: bacterial cell targeting, eukaryotic cell 
targeting, bacterial and eukaryotic cell targeting, and conjugation/gene-regulation/cellular 
adhesion (167-170).  The T6SS is a syringe-like assembly composed of at least 13 
different core subunits (171,172) that form a base plate, a contractile sheath, a non-
contractile tube within the contractile sheath, and a tail spike complex (173,174).  This 
system cycles from needle polymerization, to contraction, and disassembly.  The best 
characterized example of this rapid turnover can be seen in V. cholera (174).  There are 
also gene clusters that encode accessory proteins required for proper assembly and 
function of the apparatus, however, their exact functions are not fully understood (16,175).  
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Figure 1-7:  Models of inactivated to the activated state of the type VI secretion 
system. The three membrane-associated proteins TssL, TssM, and TssJ form a complex 
channel bound to the peptidoglycan layer via TssL. The pilus filament, Hcp, and the VgrG 
trimer are anchored to the system via interactions to the membrane bound proteins. 
Activation of the T6SS results in effector delivery to a target cell through the Hcp tube.  
Adapted from Silverman et al. 2011 (16). 
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Type VII secretion system 
The final known secretion system is the T7SS utilized by pathogenic mycobacteria.  
In mycobacteria, T7SSs are also known as the ESX system.  In the T7SS there can be up 
to five different loci found in a single species of Mycobacterium, however, most species 
only contain one to two loci (176,177).  The substrates for mycobacteria T7SSs contain no 
signal sequence for Sec or Tat secretory systems.  However, all T7SS subunits have 
predicted α-helical transmembrane domains, suggesting that these proteins are inserted 
into the inner membrane.  There is also evidence that one of these membrane proteins, 
EccE, spans both membranes (178).  Additional components seem necessary to complete 
the secretion across the outer membrane.  Current data fail to clarify what type of structure 
is involved in performing this role in the mycomembrane/OM.  The only well-studied 
mycomembrane protein is MspA from Mycobacterium smegmatis, which forms pores in 
this non-pathogenic mycobacterium.  The crystal structure of MspA reveals an atypical 
octomeric β-barrel (179).  So far, there is no evidence for mycobacteria utilizing β-barrel 
structures, because the channel can be formed by a ring of amphipathic α-helices, similar 
to the initial steps of T4SS assembly (180). 
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Figure 1-8:  Model of the type VII secretion system. In this model, the substrate is 
transported from the inner membrane to the extracellular space, denoted in light blue and 
light grey. First, the substrate dimer is targeted for secretion through the recognition of the 
carboxy‑terminal signal sequence by the cytoplasmic protein Rv3871. Rv3871 interacts 
with Rv3870 at the cell membrane to form an active ATPase. The Rv3781–Rv3780 
complex could form a hexameric ring structure with a central cavity that propels ESX‑1 
substrates through the secretion channel.  Adapted from Abdallah et al. 2007 (17). 
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Gatekeeper proteins 
As noted above, the T3SS requires a group of proteins called gatekeepers to 
regulate T3SS activity (126-131).  Gatekeeper-null strains display severely dysregulated 
secretion assembly, effector secretion, and overall reduced virulence (131,181).  
Gatekeepers can be subdivided into the YopN-TyeA family and the MxiC family(133).  The 
difference between the two sub-families is whether the gatekeeper is two proteins (i.e., 
YopN-TyeA) or one protein (MxiC) (133).  Both of these sub-families of proteins are known 
to control the secretion of effector proteins from the T3SS (127,128,131,133,181,182). 
The mechanism by which gatekeepers regulate secretion is unclear, but a common 
deletion phenotype is constitutive effector secretion and poor translocator secretion (131).  
Gatekeeper mutants that lack an amino-terminal secretion signal are not secreted, which 
also prevents translocator secretion (131).  From mutational studies, it has become evident 
that functional gatekeepers are needed for effective translocator secretion and subsequent 
formation of the translocon in the host cell.  This translocation pore is essential for effector 
secretion into the host cell and thus T3SS function(183). 
Gatekeepers are essential, and if absent or altered, the T3SS cannot properly 
release its effectors.  In addition to this important role, gatekeepers can also acquire 
effector functions, as has been seen in two cases.  The Pseudomonas syringae HrpJ 
protein acts as a virulence factor inside plant cells and suppresses PAMP-triggered 
immunity (184), and in Chlamydia pneumoniae, CopN, which is the focus of this thesis, 
causes mitotic arrest by sequestering αβ tubulin and preventing microtubule assembly in 
eukaryotic host cells (185,186).  
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Chlamydia background 
Chlamydiae are gram-negative, obligate eukaryotic parasitic bacteria that have 
been implicated in the etiology of a wide range of human diseases.  Three notable 
Chlamydia species are pathogenic to humans: C. trachomatis, C. psittaci, and C. 
pneumoniae (187-189).  C. trachomatis infections result in pelvic inflammatory disease, 
infertility, and are major causes of preventable blindness in infants (187-190). C. psittaci 
causes acute respiratory disease (psittacosis).  C. pneumoniae causes community-
acquired pneumonia (CAP), bronchitis, asthma, contributes to atherosclerosis, and 
perhaps  central nervous system disorders as well (187-189).  All Chlamydia use a similar 
mode of infection, shown in Figure 1-9, including phases of phagocytosis to endosomes, 
entry, spread, and proliferation (187).  Chlamydiae have a biphasic life cycle consisting of 
metabolically inactive elementary bodies (EBs) and metabolically active reticulate bodies 
(RBs) (191).  Infection involves attachment and cellular uptake of EBs and subsequent 
differentiation into RBs.  The RBs remain in endosome-derived membrane vacuoles 
termed ʻinclusionsʼ which migrate to the microtubule, MT, organizing center (MTOC) in a 
dynein and MT-dependent process (192-194).  After several replications, RBs re-
differentiate into infectious EBs and spread to neighboring cells (191).  The molecular 
mechanisms that Chlamydiae utilize to invade the host cell are not well understood.  
However, it is known that Chlamydiae, use a type III secretion system (T3SS) to 
translocate effector proteins into the host cell to modulate host cell function (188,195-199).  
Chlamydiae deliver effector proteins across inclusion membranes to direct host cell 
processes (200).  After entry, Chlamydiae secrete inclusion membrane proteins (Inc) family 
effectors termed modify the inclusion.  These modifications prevent degradation or 
trafficking of the inclusion to the Golgi complex (201-203).  Once modified by Inc proteins, 
the inclusion is trafficked to the MTOC, where it associates with the host centrosome and 
alters the MT network (204,205). 
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Although the importance of a T3SS is established, the mechanisms by which 
effectors subvert host defenses and enable colonization are not fully understood.  The 
focus of this proposal is the protein CopN from C. pneumoniae, which arrests cell growth in 
metaphase (185).  This cell cycle arrest has been attributed to alterations in the 
microtubule cytoskeleton (185).  While T3SS effectors are known to target the host actin 
cytoskeleton, to date no T3SS effector has been shown to target the tubulin cytoskeleton.  
CopN is novel in that it targets microtubules (MTs), but it is not known how CopN interacts 
with and disrupts the microtubule network.  This thesis will describe experiments that 
establish a mechanism by which CopN disrupts MT structures as well as describing how 
CopN regulates T3S. 
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Figure 1-9: The Chlamydia life cycle. (A) Elementary bodies attach to the host cell; (B, 
C) Elementary body entry and formation of the inclusion; (D) modification and 
translocation of inclusion; (E) differentiation of elementary body to reticulate body; (F) 
replication of reticulate body; (G) redifferentiation of reticulate bodies to elementary bodies; 
(H) cell lysis and release of elementary bodies, which allow the pathogen to spread to other 
host cells.  Adapted from Engel 2004 (187). 
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Microtubules 
Microtubules are a component of the eukaryotic cytoskeleton, and are essential for 
moving cellular structures such as organelles, chromosomes, and other cargo throughout 
the cell (206).  Microtubules are dynamic polymers composed of 13 protofilaments, each of 
which are built from αβ tubulin heterodimers (207).  Microtubules are polar filaments, which 
grow and collapse rapidly at the plus end (207,208).  The microtubule polymer is oriented 
in such a way that the αβ tubulin heterodimers are arranged by the α subunit oriented 
towards the minus end of the growing MT, towards the anchor point, and the β subunits are 
oriented in the growing or plus end of the MT (206).  Thus, the MT is a polymer of αβ 
tubulin heterodimers that are aligned head-to-toe. In mammalian cells, the minus-end of 
the MTs are anchored centrosomes (209).  In yeast, MTs are anchored to the spindle pole 
body (210).  A growing microtubule is formed by GTP/GDP-bound αβ tubulin heterodimers: 
α-tubulin subunit has a bound molecule of GTP, that does not hydrolyze (206,207); and the 
β-tubulin subunit can bind either GTP or GDP, depending on whether the GTP is 
hydrolyzed or not.  MTs polymerize via addition of GTP-bound tubulin subunits, which will 
hydrolyze once incorporated into the MT lattice (211).  A semi stable GTP-tubulin cap is 
formed at the growing end of the MT, which suppresses a change in equilibrium towards 
disassembly, called catastrophe (211).  In vitro, the GTP cap is estimated to be ~100-200 
αβ tubulin heterodimers (212).  However, in vivo, the GTP cap is measured to be 
composed of ~750 αβ tubulin heterodimers (211). 
As mentioned above, microtubules have the ability to move cellular structures 
throughout the cytoplasm.  By maintaining its attachment to a particular structure, the 
microtubules can move its cargo by growing and shrinking (213).  Given this movement 
and force that is generated, MTs are molecular machines that converts chemical energy 
into mechanical force, which has been shown to be equivalent to motor proteins (206,214). 
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There are many proteins that are associated with microtubules.  These proteins 
either aid in modulating microtubule dynamics, or utilize the MT as a means for 
transportation.  Microtubule associated proteins, MAPs are one class of proteins that 
modulate microtubule dynamics by increasing stability of the MT causing increase growth 
rate by cross-linking adjacent protofilaments (215,216).  Aside from MAPs, there are two 
classes of microtubule end binding proteins: mitotic centromere-associated kinesins, 
MKACs, which bind to microtubule ends and cause destabilization (217); and, plus end 
binding proteins, +TIPs, which bind and stabilize the growing end of the microtubule, and 
have a conserved tubulin binding TOG domain (218-221).  Another modulatory protein, 
Op18/stathmin, sequesters two tubulin heterodimers, which promotes MT catastrophe by 
decreasing the free tubulin concentration in the cell (222-226). However, this function is 
dependent on the phosphorylation state of stathmin. Unphosphorylated stathmin 
destabilizes microtubules by reducing the concentration of tubulin in the cell needed to 
form MTs; and, phosphorylated stathmin cannot bind tubulin heterodimers, which allows 
MTs to grow (227-233). 
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Figure 1-10: Microtubule dynamics. Microtubules are filamentous polymers, which 
switch between growth and shrinkage.  Tubulin heterodimers are incorporated into the 
growing microtubules.  In growing microtubules, GTP bound αβ tubulin heterodimers form 
GTP-caps at the plus end of the microtubule.  The loss of the GTP-cap results in a 
switching from MT growth to MT shrinkage.  Adapted from Conde & Cáceres 2009 (208). 
  
 
	   32	  
Research objective 
CopN is secreted by the T3SS (196,234) and shows sequence similarity to other 
T3SS gatekeepers (133,235).  Heterologous expression of CopN in cells results in loss of 
microtubule spindles, disruption of metaphase plate formation, and causes mitotic arrest, 
leading to the classification of CopN as a secreted effector (185).  By these criteria, CopN 
is deemed a T3SS gatekeeper protein and an effector (1,30).  This combination of 
functions in a small protein motivated us to study CopN’s biochemical activities and 
structure.  Gatekeeper proteins typically block the T3SS pore; in anticipation of an 
unknown, extracellular signal which triggers gatekeeper release and effector export (31-
33).  The molecular mechanisms of microtubule networks disruption are not fully 
understood, but are known to include physical sequestration and chemical modification of 
tubulin (222,225,236-242).  My objective in this project has been to understand how CopN 
performs these two functions--gatekeeper and MT-disrupting effector--as a compact, ~400 
amino acid protein.  I have combined structural biology, biochemistry, and microbiology in 
these endeavors. 
I have shown that CopN directly binds αβ tubulin and inhibits tubulin 
polymerization into MTs.  In addition to characterizing CopN’s biochemical activity as an 
effector, I determined the structure of CopN bound to a translocator-specific chaperone, 
Scc3.  The structure identifies a previously unknown interface between gatekeepers and 
translocator chaperones and reveals that in the gatekeeper-chaperone (CopN-Scc3) 
complex the translocator-binding groove is free to bind translocators.  Structure-based 
mutagenesis of the homologous complex in Shigella reveals that the gatekeeper-
chaperone-translocator complex is essential for translocator secretion and for the ordered 
secretion of translocators prior to effectors.  Finally, I utilized the 2Å crystal structure of 
CopN and biochemical assays to elucidate the binding interface between CopN and 
tubulin.  As suggested in my previous studies, CopN disrupts microtubules by sequestering 
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αβ tubulin, in a stathmin-like mode (225,236-239).  This manuscript serves to demonstrate 
the unique dual-function of CopN: an effector protein and a general role as gatekeeper in 
the type 3 secretion system. 
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CHAPTER II 
 
THE CHLAMYDIA EFFECTOR, CHLAMYDIAL OUTER PROTEIN N (COPN), 
SEQUESTERS TUBULIN AND PREVENTS MICROTUBULE ASSEMBLY. 
 
Introduction 
 
Chlamydia species, the causative agents of a range of human diseases including 
genital, ocular and respiratory infection (187-190), are obligate intracellular pathogens with 
a biphasic life cycle consisting of metabolically inactive elementary bodies (EBs) and 
metabolically active reticulate bodies (RBs) (191).  Infection involves attachment and 
cellular uptake of EBs and subsequent differentiation into RBs.  The RBs remain in 
endosome-derived membrane vacuoles termed ‘inclusions,’ which migrate to the 
microtubule-organizing center (MTOC) in a dynein dependent process (192,193,243).  
After multiple rounds of bacterial cell division, the RBs re-differentiate into infectious EBs 
and spread to neighboring cells (191).  Chlamydia are intractable to genetic manipulation, 
complicating the task of assigning function to effector proteins, and hence, the 
development of a mechanistic understanding of interactions between Chlamydia and the 
host (188).  As with other gram-negative bacteria, Chlamydia use a type three secretion 
system (T3SS) and T3SS effectors to subvert host defenses and reprogram cell processes 
(188,196,244). 
Type three secretion is a complex pathway used by many gram-negative bacteria 
to deliver effector proteins to their hosts (for extensive reviews, please see (245,246).  The 
T3SS is composed of a needle complex (or type three secretion apparatus), an ATPase, 
translocator molecules, effector molecules, and chaperones.  The needle complex is a 
large multi-protein complex that spans both bacterial membranes and serves as a conduit 
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through which secreted proteins reach the target cell.  Proteins are secreted through this 
pore in an ATP consuming process using specialized ATPases located in the bacterial 
cytosol, at the base of the needle complex.  Secreted proteins include translocators, which 
are membrane proteins that form a pore in the host’s membrane, and effectors, which are 
a diverse group of proteins that subvert host cell processes and orchestrate bacterial 
adhesion or engulfment (among other activities).  Within the bacterial cytosol, effectors and 
translocators are often found in complex with specialized chaperones that keep them in a 
secretion competent state until secretion is initiated.  External cues initiate secretion, at 
which time a gatekeeper protein that had been occluding the pore is secreted and the 
T3SS becomes active.  A common target for T3SS effectors is the host’s cytoskeleton, 
which is frequently remodeled during infection (188,245,247-250). 
Bacterial pathogens typically secrete effectors that modulate the actin 
cytoskeleton, which enables remodeling of the membrane to promote uptake or adhesion 
of the bacteria.  The tubulin cytoskeleton is less frequently the target of effectors, although 
there are some reports describing effectors that target tubulin or MTs (185,251).  MTs are 
critical eukaryotic cytoskeletal structures (reviewed in (252)), composed principally of αβ 
tubulin and decorated with MT accessory proteins (MAPS).  In non-dividing cells, they form 
a structural network used, in combination with microtubule-associated motor proteins, for 
vesicle trafficking and organelle localization.  In motile cells they are essential components 
of cilia and flagella.  During cell division MTs form the mitotic spindle and segregate the 
chromosomes to daughter cells. 
A prominent feature of infection is that Chlamydia modulate the host’s cell cycle, 
resulting in delayed cytokinesis and failure to properly segregate sister chromosomes 
(185,192,253).  While the advantage afforded to the pathogen is not clear, two mechanistic 
strategies for affecting the cell cycle have been identified: regulation of the G2/M transition 
by cleavage of mitotic cyclin B1 (253) and a CopN-dependent mitotic arrest (185). 
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Expression of CopN in eukaryotic cells results in severe alterations in the MT 
network, including destruction of mitotic spindles (185).  CopN is a putative T3SS 
gatekeeper protein (133,196).  Gatekeeper proteins typically block the secretion pore 
allowing protein export only in the presence of an unknown extracellular signal 
(103,129,254).  The discoveries that CopN was a T3SS effector (196) that destroyed MT 
networks (185,196), as well as a putative gatekeeper protein (133,235) motivated us to 
determine CopN’s biochemical activity.  This chapter shows that CopN directly binds αβ 
tubulin and inhibits tubulin polymerization into MTs. 
 
 
Methods 
 
Purification of His tagged proteins. 
Gateway expression vectors for CopN from C. pneumoniae, C. trachomatis, and C. 
psittaci B577 (C. abortus) were previously described (185).  C. pneumoniae  CopN was 
subsequently cloned by standard PCR methods into pET28, thus incorporating an amino-
terminal hexa-histadine tag, and all truncations were made in pET28 using PCR based 
mutagenesis. Scc2 and Scc3 were PCR amplified from genomic DNA (ATCC strain AR-39) 
and cloned into pET28, with an amino-terminal hexa-histadine tag.  Human stathmin was 
sub-cloned from a pET15 vector into pET28 and fused to an amino-terminal hexa-histadine 
tag.  Proteins were expressed in BL21 (DE3) cells grown in LB at 37˚C and induced with 
0.1mM IPTG for 12 hours at 20 ˚C.  Bacteria were harvested by centrifugation, lysed with a 
French Press, and proteins were purified by metal affinity chromatography and, for all 
proteins except stathmin, size exclusion chromatography.  Proteins were snap-frozen in 
liquid nitrogen and stored at -80 ˚C until needed. 
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Tubulin purification. 
Fresh bovine brains were obtained from a local slaughterhouse (C and F Meat 
Company, College Grove, TN) and tubulin was prepared as described (255), with the only 
modifications being that 600 g of bovine brains rather than 1 Kg of porcine brains were 
used (buffer volumes were adjusted accordingly) and that the rotors used were a JA-10, Ti-
45, and Ti-70.1 rather than SLA 1500, Ti-45, and TLA 100.4 (rotor velocities were adjusted 
to achieve appropriate g forces).  Tubulin was snap-frozen in BRB80 buffer (80mM PIPES, 
1mM MgCl2, 1mM EGTA, pH 6.8) in liquid nitrogen and stored at -80 C until needed. 
 
Size exclusion chromatography. 
Tubulin and chaperone binding assays were performed by size exclusion 
chromatography, using a 24 mL Superdex S200 column (GE Healthcare), equilibrated in 
S200 buffer (10mM Tris-HCl, 150mM NaCl, pH 7.5), run at 0.5 mL/min, and maintained at 
4˚C.  CopN and tubulin, or CopN and Scc3 were mixed, allowed to form complexes for 15 
minutes, and applied to the column.  For the stathmin-tubulin-CopN experiments, stathmin 
and tubulin were mixed first, allowed to equilibrate for 15 minutes, then CopN was added 
and allowed to equilibrate for an additional 15 minutes. 
 
Microtubule pelleting assays. 
MT pelleting assays were performed essentially as described (222,256). 10 mg/rxn 
of Taxol stabilized MTs, were incubated with 2, 6, 10, 20. 30, 40 mg/rxn of the CopN∆84 for 
15 minutes at 25˚C and spun through a 60% sucrose cushion (20 min at 140 K x g in a 
TLA 100.4 rotor).  Fractions from the supernatant and pellet were analyzed by SDS PAGE.  
Human stathmin (5 mg/rxn) and rat microtubule associated protein 2c microtubule-binding 
domain (257) (MAP2c MTBD: used at 20 mg/rxn) were used as positive and negative 
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controls, for MT binding, respectively.  MAP2c MTBD was a gift from Kevin Slep, University 
of North Carolina, Chapel Hill. 
 
Tubulin turbidity assays. 
Turbidity assays were performed in triplicate in a BioTek Synergy 4 plate reader in 
96 well plates.  Each assay well included 200 µg of tubulin, 3mM GTP, 80mM PIPES, 2mM 
MgCl2, 0.5mM EGTA, and 30% glycerol in 300 µL total volume.  Plates were setup on ice, 
mixed, and transferred to an incubated plate reader maintained at 37˚C, absorbance at 340 
nm was measured at 45 s intervals, and the plates were shaken for 5 s before each 
measurement.  Data presented are the average of three replicate wells.   
 
Microtubule disassembly. 
MT disassembly was assayed essentially as described (222,256,258).  Surfaces of 
double-stick tape flow cells were coated with 1 mg/ml biotinylated BSA followed by 
0.1mg/ml streptavidin, 1mM fluorescent (1:9 rhodamine-labeled:unlabeled), biotinylated 
(1:100 biotinylated:unmodified) GMPCPP-MTs were then bound to the flow cell surface, 
and washed with flow cell buffer (FCB; 80mM Pipes, pH 6.8, 0.5mM MgCl2, 1mM EGTA 
containing 1mM MgATP, 500 mg/ml casein, 50mM KCl, and an oxygen scavenging mix 
(259).  CopN was diluted to 2.8 µM in FCB and added to the flow cell. MT disassembly was 
monitored by time-lapse fluorescence microscopy using a Nikon 90i epifluorescence 
microscope with a 100X 1.4 NA Nikon objective and a CoolSNAP HQ2 cooled CCD 
camera.  MT lengths were measured at 0 and 4 minutes.  These experiments were 
performed simultaneously with experiments presented in Du et al. 2010 (256), therefore, 
the control experiments represent the same set of controls reported in that publication. 
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Electron microscopy. 
GMPCPP stabilized MTs were prepared as described (260).  Microtubules were 
mixed with either buffer alone (BRB80), MAP2c MTBD (a known MT bundling protein 
(257), or CopN and incubated for 5 minutes at room temperature before being prepared for 
imaging by conventional negative stain electron microscopy.  Uranyl formate stained 
samples were prepared for EM as described (261).  In brief, 3 ml of sample was absorbed 
to a glow discharged 200-mesh copper grid covered with carbon-coated collodion film.  The 
grid was washed with two drops of water and then stained with two drops of uranyl formate 
(0.75%).  Samples were imaged on a FEI Morgagni electron microscope operated at an 
acceleration voltage of 100 kV.  Images were recorded at a magnification of either 11,000X  
or 36,000X and collected using a 1K x 1K CCD camera (ATM). 
 
Competitive binding assay. 
This assay was performed analogously to a competitive ELISA.  Wells in a 96 well 
microtiter plate were coated with 1 mg/well tubulin in BRB80 for 10 hrs at 4˚C.  The plate 
was subsequently washed 2 times with PBS, blocked for 2 hrs with PBS/3% BSA at 22˚C, 
and washed 4 times with PBS.  Biotinylated stathmin, labeled with sulfo-NHS-Biotin 
(Thermo-Scientific) following the manufacturer’s protocol and using a 40 fold molar excess 
of sulfo-NHS-Biotin, was added simultaneously with unlabeled CopN to each well.  100mL 
of 2.0mM biotin-stathmin was added to each well.  This value was the EC50 of biotin-
stathmin in experiments without CopN.  100mL CopN was added as a dilution series from 
10mM to 0.020mM.  To add these reagents simultaneously, and avoid order of addition 
kinetics, they were pre-mixed in a 96 well plate with very low protein binding in 
PBS/3%BSA/0.05% Tween 20.  Binding was for 2 hrs at 22 ˚C followed by 4 PBS washes.  
The biotin signal was developed with alkaline phosphates linked streptavidin using 
reagents from Kikegaard and Perry Laboratories and read on a BioTek Synergy 4 plate 
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reader at 405nM.  Control experiments included conditions without tubulin, without CopN, 
and without biotin-stathmin.   
 
 
Results 
 
Domain mapping experiments demonstrate that CopN encodes three domains. 
CopN, which is found in all Chlamydia species, shows weak sequence homology 
to a family of bacterial proteins that function as gatekeeper proteins for the T3SS (133).  
This family includes YopN from Yersinia pestis and MxiC from Shigella.  Gatekeeper 
proteins exist in two different organizational structures, a YopN-like form in which the 
gatekeeper and a regulator protein (TyeA in the case of YopN) exist as two separate 
polypeptides (103), and a single polypeptide form exemplified by MxiC, the T3SS 
gatekeeper protein from Shigella (254).  In MxiC a TyeA-like domain is present in the 
carboxy terminal region of the protein (254).  CopN is ~100 amino acids longer than YopN 
(399 versus 293 amino acids), ~50 amino acids longer than MxiC (399 versus 354), and 
has been proposed to be a MxiC-like gatekeeper protein (133). 
As a first step in the biochemical characterization of CopN, I mapped its domain 
structure by limited proteolysis and mass spectrometry, using trypsin and chymotrypsin.  
This approach, in which unstructured regions are rapidly degraded, identifies domains 
based on protease resistance.  My results, summarized in figure 2-1, indicate that CopN is 
composed of a flexible amino-terminus, a protease resistant central core, and a protease 
resistant carboxy terminal domain.  Despite very low sequence identity (45 conserved 
residues between CopN and MxiC), this domain structure is similar to the domain 
organization of MxiC (254).  This domain structure has two implications: First, that amino 
acids 85-268 form a gatekeeper domain that is structurally similar to YopN and the 
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gatekeeper region of MxiC.  Second, that the carboxy terminal ~130 amino acids of CopN 
form a regulatory domain, perhaps similar to TyeA and the carboxy terminal domain or 
MxiC, which controls CopN secretion and hence activation of the T3SS.  In the case of Y. 
pestis, TyeA binds the carboxy-terminus of YopN and prevents YopN’s secretion until an 
unknown signal promotes the release of TyeA (103).  In the case of CopN, and other MxiC-
like gatekeeper proteins, secretion is likely triggered by a conformational change within the 
carboxy-terminal domain, rather than by release of a regulatory protein. 
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Figure 2-1: Domain structure of CopN as determined by limited proteolysis.  A.  SDS 
PAGE of limited proteolysis with trypsin shows two bands ∆84 and ∆268 that were 
unambiguously identified by mass spectrometry.  B.  The deduced domain structure of 
CopN. Based on limited proteolysis data and the MxiC structure (254), the first 84 residues 
are a flexible leader, residues 85-269 are a putative “gatekeeper” domain, and residues 
269-399 are a putative regulatory domain.  C.  Size exclusion chromatography trace 
showing that Scc3 and CopN co-elute, resulting in a shift of Scc3 and CopN when the 
proteins are added together, relative to when they are added separately.  D.  Size 
exclusion chromatography trace showing ∆84 CopN interacts with Scc3 similarly to full 
length CopN. 
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CopN binds Scc3, a class II chaperone, using regions outside the unstructured amino 
terminus. 
The amino-termini of type three secretion effectors are unstructured and function to 
promote secretion, with some binding cognate chaperones and becoming partially ordered 
upon binding (100,104,246,262).  To determine if the amino-terminal region of CopN binds 
a chaperone, I first identified the relevant chaperone.  The candidate chaperone, Scc3, 
which was shown to bind CopN in both yeast and bacterial 2-hybrid experiments (234,235), 
was cloned, expressed, and purified.  Using purified components, I found the Scc3 
promotes a shift of CopN, as well as an amino-terminal truncation of CopN (∆84 CopN), to 
faster elution time on a size exclusion chromatography column, and that when added 
together the proteins co-elute at the faster time, indicating that Scc3 binds directly to CopN 
(figure 2-1, figure 2-2).   
 
CopN binds directly to tubulin, but not to microtubules. 
 Over-expression of C. pneumonia CopN in eukaryotic cells results in both 
disruption of mitotic spindles, which are composed of MTs, and mitotic arrest (185).  Such 
characteristics are consistent with the action of a MT destabilizing protein, motivating us to 
investigate the possibility that CopN binds tubulin or MTs.  Using purified components I 
show that CopN binds directly to αβ tubulin.  Using size exclusion chromatography to 
measure protein-protein interactions as a shift in retention time, the data show that CopN 
significantly retards the retention time for αβ tubulin (figure 2-3A, figure 2-4A,B), consistent 
with a model in which the disruption of mitotic spindles observed when CopN is expressed 
is mediated by direct tubulin binding.  I next investigated whether additional homologs 
bound αβ tubulin.  As shown in figure 2-3B and figure 2-4C, CopN from C. psittaci B577 (C. 
abortus), but not from C. trachomatis (figure 2-3C, figure 2-4D), interacts with αβ tubulin by 
size exclusion chromatography. 
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To determine whether CopN bound to both MTs and tubulin, or if it was specific for 
unpolymerized tubulin, CopN was evaluated for ability to bind MTs using a MT pelleting 
assay.  In this assay CopN was incubated with MTs, which were subsequently separated 
from free αβ tubulin by centrifugation.  This assay is typically used to show binding to MTs, 
in which case the binding partner is pulled to the pellet with the MTs.  As shown in figure 2-
3D, CopN remains in the supernatant, indicating that it does not bind MTs.  Although this 
experiment can’t rule out that a small amount of CopN’s binds to MTs, taken in its entirety, 
figure 2-3 shows that CopN has a clear preference for un-polymerized tubulin, indicating 
that it binds a surface of tubulin that is inaccessible or altered in MTs.  With the assistance 
of Dr. Melanie Ohi, we further evaluated the possibility that CopN might induce bundling or 
some other alteration of MTs.  Negative stain Electron Microscopy (EM) demonstrates that 
CopN does not alter MT structure (figure 2-5). 
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Figure 2-2: SDS-PAGE and size exclusion chromatography traces of CopN-Scc3 
complexes.  A. and B.  SDS-PAGE shows that the peaks from the chromatographs 
contain the expected components.  The shifted CopN + Scc3 peaks contain both CopN 
and Scc3. 
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Figure 2-3:  CopN binds tubulin, but not microtubules.  A., B., and C. show size 
exclusion chromatography based binding assays, in which proteins are run individually and 
as a mixture on an analytical size exclusion chromatography column.  In these traces, 
CopN is red, tubulin is blue, and the complex is green.  In panels A. and B. CopN + Tubulin 
runs faster than either individual component, indicating that the purified proteins directly 
associate. Panel C. indicates that C. trachomatis CopN does not bind tubulin tightly enough 
to survive size exclusion chromatography. Panel D. shows a MT pelleting assay.  In this 
assay, Taxol stabilized MT are prepared, mixed with C. pneumoniae CopN, stathmin, or 
MAP2c and fractionated between a soluble (S) tubulin containing fraction and an insoluble 
(P) MT containing fractions by centrifugation.  CopN fails to co-pellet with MTs, indicating 
that it doesn’t bind MTs.  Taken together with panels A. and B., these data indicate direct 
binding between CopN and tubulin, but not between CopN and MTs. 
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Figure 2-4: SDS-PAGE and size exclusion chromatography traces of CopN-tubulin 
complexes.  A.-D.  SDS-PAGE shows that in all cases where addition of CopN shifted the 
position of the CopN or tubulin peaks, the shifted peaks from the chromatographs contain 
both tubulin and CopN. C. pneumoniae ∆29 CopN, C. pneumoniae ∆84 CopN, and C. 
psittaci CopN form stable complexes with tubulin that survive size exclusion 
chromatography, CopN from C. trachomatis does not form a size exclusion 
chromatography resistant complex with tubulin. 
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Figure 2-5: CopN does not induce microtubule bundling.  Images of GMPCPP 
microtubules mixed with buffer, MAP2c MTBD, or CopN∆84. Left panel, 11,000X 
magnification and scale bar, 200 nm. Right panel, 36,000X magnification and scale bar, 
100nm. (A) Representative EM images of microtubules incubated with buffer. (B) 
Representative EM images of microtubules incubated with MAP2c MTBD, a known MT 
bundling protein. (C). Representative EM images of microtubules incubated with C. 
pneumoniae  ∆84 CopN. 
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CopN inhibits microtubule polymerization, but does not de-polymerize microtubules. 
The direct interaction between CopN and αβ tubulin and the lack of a detectable 
interaction between CopN and MTs led us to hypothesize that CopN promotes MT 
instability by binding and sequestering αβ tubulin, thus preventing polymerization.  That is, 
CopN might sequester αβ tubulin and effectively raise the critical concentration of 
assembly for tubulin.  Stathmin, a eukaryotic tubulin binding protein, is known to use an 
analogous “sequestration” mechanism to prevent tubulin polymerization (225,236-239).  To 
evaluate how tubulin binding by CopN alters MT polymerization, I optimized a standard, MT 
turbidity assay (222) for a 96 well plate.  In this assay, tubulin is incubated at 37 ˚C and 
allowed to polymerize into MTs, which scatter light.  Absorbance at 350nM is measured as 
an indicator of polymerization.  Use of a 96 well format allowed us to directly compare all 
proteins in very uniform conditions.  CopNs from C. pneumonia and C. psittaci strongly 
inhibit tubulin polymerization, whereas CopN from C. trachomatis shows weaker, but 
measurable inhibition (figure 2-6A).  CopN from C. pneumonia was particularly effective at 
inhibiting MT formation, showing near complete inhibition at 25 µM.  Consistent with the 
observation that CopN binds free αβ tubulin but not MTs, I also observe that it inhibits αβ 
tubulin polymerization, but does not promote depolymerization of MTs.  With the aid of Dr. 
Ryoma Ohi and Dr. Yaqing Du, I evaluated the ability of CopN to destabilize MTs by mixing 
CopN with preformed, rhodamine labeled MT, as described (256,258).  As shown in figure 
2-6B, no change in MT size is evident following incubation with CopN. 
The similar capacities of both CopN and stathmin to bind free tubulin and inhibit 
polymerization motivated us to determine whether CopN is a distant prokaryotic stathmin 
homolog.  Stathmins contain multiple copies of an ~35 amino acid tubulin binding repeat 
(TBR), each of which binds a single αβ tubulin (263).  I was unable to identify regions of 
CopN with TBR-like sequence motifs, and chose to test experimentally, the idea that CopN 
might bind to a similar site on tubulin.  I focused on the carboxy terminal gatekeeper 
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domain (∆84 CopN) because longer constructs form dimers in size exclusion 
chromatography conditions, complicating the experiments.  I evaluated ∆84 CopN’s 
capacity to bind stathmin-tubulin complexes and form a super-shifted T2S-C complex 
(stathmin bound to 2 αβ tubulin dimers bound to one or more CopN’s).  As shown in figures 
2-7 and figure 2-8, CopN does not interact with the T2S complex, consistent with a CopN-
tubulin interface that physically overlaps with the stathmin-tubulin interface.  I verified this 
result with a competition binding experiment and showed that CopN competes with 
biotinylated stathmin for binding to immobilized tubulin (figure 2-7). 
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Figure 2-6:  CopN inhibits tubulin polymerization, but doesn’t depolymerize 
microtubules.  A. Tubulin polymerization experiment.  Curves represent extent of tubulin 
polymerization as monitored by light scattering.   Controls of Taxol and Vinblastine indicate 
the dynamic range of the assay.  The “No Drug” curve indicates the expected time course 
and extent of polymerization for tubulin alone under these conditions (6 µM tubulin, 30% 
glycerol).  All CopN’s show some level of inhibition, with C. pneumoniae showing inhibition 
nearly as strong as Stathmin.  B.  MT disassembly assay showing that CopN is unable to 
disassemble preformed MTs.  The top, middle, and bottom panels show 3 time points each 
for untreated, CopN (2.8mM), and MCAK (25nM) treated MTs. Scale bars are 6mm.  D.  
Depolymerization rates calculated from measured MT lengths at t=0 and t=4 minutes for 
CopN, buffer, and MCAK (mitotic centromere associated kinesin, kinesin 13) a well known 
MT depolymerase (264). 
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Figure 2-7:  CopN is unable to bind to stathmin-tubulin complexes.  A.  Size exclusion 
chromatograph showing that ∆84 CopN is unable to shift a stathmin-tubulin complex.  B. 
and C.  SDS-PAGE on fractions from A.  Panel A. shows SDS-PAGE from the stathmin-
tubulin complex, which verifies that the peak for the stathmin-tubulin complex is located at 
~13.5 mLs, and demonstrates that this peak contains both stathmin and tubulin.  Panel C. 
shows SDS-PAGE from the stathmin-tubulin complex mixed with CopN, and indicates that, 
under these conditions, CopN displaces stathmin from the stathmin-tubulin complex.  The 
CopN-tubulin peak is at ~13.5 mLs, but stathmin is centered at ~16 mLs.  Stathmin is 
invisible in the chromatograph because it lacks tryptophans.  D. A competition binding 
experiment in which mixtures containing a fixed (2mM) biotin-stathmin concentration and 
decreasing (from 10 to 0.020mM) unlabeled CopN were added to tubulin coated wells and 
biotin-stathmin binding was measured with alkaline phosphatase linked streptavidin. 
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Figure 2-8: SDS-PAGE of controls from CopN-tubulin-stathmin super complex 
formation attempts.  A.-D.  SDS-PAGE of fractions from the CopN ∆84, tubulin, stathmin, 
and tubulin + CopN ∆84 size exclusion chromatography experiments described in the text 
and presented in figure 2-7.  The chromatographs are shown in E. 
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Discussion 
 
CopN is a multifunctional Chlamydial effector protein functioning both as the T3SS 
gatekeeper protein and as a secreted effector protein that causes mitotic arrest 
(133,185,196,235).  Thus far, CopN is the only gatekeeper protein known to also function 
as an effector.  As such, it is perhaps not surprising that CopN’s chaperone use is also 
unusual. 
T3SS chaperones are typically grouped by substrate function, with class I 
chaperones binding effectors, class II binding translocators, and class III binding 
components of the needle complex (245,265).  The functional grouping into class I and 
class II chaperones corresponds with conserved structural characteristics.  Class I 
chaperones are dimeric mixed α/β proteins composed of 5 beta strands and 3 alpha 
helices (245).  Class II chaperones are monomeric all a helical tetricopeptide (TPR) 
proteins (266-268). 
I show that CopN binds directly to Scc3 (figure 2-1), in agreement with results 
obtained from yeast and bacterial 2-hybrid experiments (234,235).  Scc3 is similar to SycD 
from Yersinia and IpgC from Shigella, both of which are class II chaperones with a TPR 
fold (266-268).  These biochemical studies demonstrate that this interaction is direct and 
robust, as it survives purification by size exclusion chromatography.  Further, this 
interaction involves regions outside the flexible amino-terminus of CopN indicating that 
CopN’s interaction with Scc3 is unique both in the structural details of the interaction and in 
that it binds a class II chaperone, which usually interact with translocators, rather than a 
class I or class III chaperone, which typically bind effectors and needle components, 
respectively (245). 
CopN is both a putative component of the secretion complex and an effector, yet 
interacts with a chaperone typically reserved for translocators.  It appears that gatekeeper 
	   55	  
proteins do not have conserved chaperone uses, with YopN utilizing a class I chaperone 
(103) and CopN using a class II chaperone. 
I have shown that CopN directly binds αβ tubulin and inhibits MT formation (figures 
2-3 and 2-6).  CopN does not bind or depolymerize existing MTs (figures 2-3 and 2-6), 
suggesting that its mechanism of action is through binding of αβ tubulin.  Stathmin, a 
eukaryotic tubulin binding protein, also reduces MT assembly by binding free tubulin 
(225,236-239).  CopN lacks the consensus TBR sequences that are conserved among 
highly divergent stathmins (263) and lacks any detectable sequence identity with 
stathmins.  Although stathmin and CopN share no sequence identity, both inhibit MT 
assembly by binding free αβ tubulin, suggesting that Chlamydia have independently 
evolved an activity with similarity to stathmin. 
MT formation is a non-equilibrium assembly process in which GTP hydrolysis by 
the b tubulin subunit (269) is coupled to polymerization (252).  MTs are intrinsically 
dynamic, exhibiting two types of dynamic behavior; dynamic instability (270) and 
treadmilling (271).  Dynamic instability refers to the observation that under identical 
conditions MTs alternate stochastically between polymerization and depolymerization 
(270).  Treadmilling refers to the observation that MTs can simultaneously grow at one end 
and shrink at the other, a process that consumes GTP but results in no net change in MT 
length (271).  These two processes ensure that MTs and free αβ tubulin readily 
interconvert, thus allowing proteins that target free αβ tubulin to influence polymerization.  
Polymerization is a bimolecular event in which two tubulin dimers or a tubulin dimer and a 
growing MT combine.  As such, the rate of polymerization is influenced by the 
concentration of αβ tubulin, and proteins that reduce or increase the effective concentration 
of αβ tubulin affect polymerization rates.  Within eukaryotes, a class of proteins, plus end 
binding proteins (+TIPS), enhances polymerization by binding MTs and free tubulin in a 
productive configuration (220,272,273).  Stathmins, a much smaller group of proteins, 
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restricted to a single protein family with homologues throughout the kingdom of eukaryotes, 
bind tubulin in such a way as to block interfaces necessary for assembly.  In so doing, 
stathmins lower the concentration of assembly-competent tubulin, reduce MT assembly, 
and destabilize MTs (222,225,236-242).  Chlamydia have independently evolved CopN to 
exhibit a similar biochemical function. 
Regulation of MT assembly is a mechanism to control cell division utilized by both 
stathmin and CopN (185,238,274).  Stathmin regulates MT assembly in a cell cycle 
dependent manner, achieved by cell cycle dependent phosphorylation of stathmin, which 
reduces its inhibitory effect and allows cytokinesis to proceed (238,274).  CopN also 
inhibits cell division (185), but two significant distinctions between these proteins, despite 
similar mechanisms, should be noted.  While stathmin is highly abundant (238) and its 
activity is regulated, allowing cell division (274), no such regulation of CopN is known.  
Further, T3SS effectors are secreted in fairly small quantities –this has only been 
measured once, for SipA from Salmonella, where ~6,000 molecules per bacteria are 
secreted (275)– implying that similar biochemical functions are utilized in different ways to 
promote similar outcomes.  CopN over-expression disrupts MTs and causes mitotic arrest 
(185), but it is unclear how many copies of CopN are required for this effect.  It is known 
that during infection Chlamydia do not disrupt the host’s cell-cycle until the infections are 
fairly dense (191), which can be ~1,000 bacteria per host cell (276-278).  Thus, CopN 
could be present at very high levels in cells.  Since αβ tubulin is present at millimolar 
concentrations (~25 million molecules) (279,280) in cells, CopN must either be abundant or 
targeted to the site of tubulin polymerization for αβ tubulin sequestration to significantly 
alter MT assembly.  Chlamydia are indeed located at or near the MTOC (192,193,243), 
thus a mechanism involving tubulin sequestration at the site of tubulin polymerization 
seems likely.  It remains to be determined if additional MT disrupting functions can be 
attributed to CopN.  From this data I cannot rule out the possibility that CopN bound αβ 
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tubulin might also be sub-stoichiometrically incorporated into MTs causing additional 
changes in MT dynamics. 
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CHAPTER III 
 
A GATEKEEPER CHAPERONE COMPLEX DIRECTS TRANSLOCATOR SECRETION 
DURING TYPE THREE SECRETION. 
 
Introduction 
 
Type Three Secretion Systems (T3SS) are conserved bacterial protein delivery 
machines used by many pathogenic Gram-negative bacteria to deliver a diverse group of 
protein molecules, termed effectors, into cells (245,281-283).  The type three secretion 
(T3S) apparatus is a conserved molecular machine that forms a protein-conducting 
channel from the bacterial cytosol to the target cell cytosol.  Major structural components of 
the T3SS include: a cytosolic-ring complex, which includes the ATPase that catalyzes 
protein unfolding and secretion; a basal-body, which forms a pore across both the inner 
and outer bacterial membranes; a needle complex, which extends from the basal-body to 
the host cell; and translocators, which form a pore in the target cell membrane, termed a 
translocon (110,284). 
The T3S apparatus secretes a diverse group of effectors directly into host cells.  
The translocon through which effectors enter the target cell is an oligomeric pore formed by 
bacterial proteins termed translocators, that are themselves secretion substrates of the 
T3SS (245).  Translocator secretion is regulated such that it occurs prior to effector 
secretion, ensuring that effector secretion occurs after a functional conduit from the 
bacterial cytoplasm to the target cell has been formed (285,286).  Efficient secretion is 
dependent on the interaction of specialized chaperones with cytosolic T3SS components 
(265).  Molecular structures have revealed two architectures for T3S chaperones: a mixed 
α/β homo or heterodimer and an all α-helical tetratricopeptide repeat (TPR) chaperone 
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(100,101,267,268,287).  These chaperones, termed class I (α/β) and class II (TPR), are 
specific for effectors and translocators, respectively (265).  The understanding of how the 
T3SS switches from translocator to effector secretion is limited, but in multiple systems this 
process is known to involve a conserved gatekeeper protein (127,128,131,133,181,182).  
Gatekeepers are encoded as one of two molecular architectures, either as two separate 
proteins (YopN-TyeA family), or as a gene fusion (MxiC family) (133).  The importance of 
this architectural distinction is unknown, and a protein fusion resulting from ribosomal 
frameshifting has been reported without an evident functional change (288). 
In Chlamydia, the gatekeeper, CopN, is known to directly bind Scc3, a 
translocator-specific chaperone (186,234,235,266,289).  Translocator-specific chaperones 
(class II chaperones) bind directly to translocators, prevent their degradation and maintain 
the translocators in a secretion competent state (265,268).  Structures from homologous 
class II chaperone/translocator pairs have revealed the chaperone to be a tetratricopeptide 
repeat (TPR) protein with a conserved binding groove that binds an amino terminal 
chaperone-binding motif on the translocator (267,268,287,290).  In addition to binding 
translocators, Scc3 also binds CopN, and although the nature of this interaction is 
unknown, it does not involve the amino terminal chaperone-binding region of CopN, and 
Scc3 is not thought to be the secretion chaperone for CopN (186,234,235,289).  It is not 
known if CopN and the Chlamydial translocators (CopB/B2) compete for the TPR binding 
groove on Scc3, if they can both bind simultaneously, or if different binding determinants 
are responsible for the Scc3-CopN interaction. 
Complexes that include gatekeepers and translocator chaperones have been 
observed in immunopurified complexes from other systems, but only as components of 
large complexes that also include other components of the T3SS (127,132,181).  Because 
such complexes are not readily accessible to structural study, I have focused structural 
studies on the gatekeeper-translocator chaperone complex from Chlamydia.  I reason that 
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the CopN-Scc3 complex is likely to be involved in the ordered secretion of translocators 
prior to effectors, a conserved phenomenon termed the translocator-effector secretion 
hierarchy. 
The origin of the translocator-effector secretion hierarchy is not fully understood, 
but has been proposed to arise from differential affinities and competition for binding sites 
either between chaperones and their effector or translocator cargo or between chaperone-
effector/translocator complexes and cytosolic components of the T3SS (100,101,291-294).  
To assess the importance of gatekeeper-translocator chaperone interactions in diverse 
pathogens, and because adequate tools and reagents for functional analysis of CopN 
mutants are not available in Chlamydia, I have extended these structural analysis with 
functional studies of MxiC and IpgC, the gatekeeper and translocator-specific chaperone 
from Shigella. 
 
 
Methods 
 
Purification of His tagged proteins. 
CopN∆84 and Scc3, from C. pneumoniae AR39, were amplified and cloned into 
pET28 with an amino-terminal hexa-histadine tag. CopN∆84 is an amino terminal 84 amino 
acid deletion of CopN.  It was previously found to be the best behaved CopN variant from 
C. pneumoniae AR39 (186).  All CopN variants were made in pET28 using PCR based 
mutagenesis and verified by sequencing.  CopN truncation mutants were designed from 
described limited proteolysis mass spectrometry analysis (186).  Proteins were expressed 
in BL21 (DE3) bacteria grown in Luria Broth at 37 ˚C.  Bacteria at an optical density (at 600 
nm) of ~0.6 were induced at 20˚C with 0.1mM isopropyl β-D-thiogalactopyranoside, and 
grown for ~12 hours.  Cultures were harvested by centrifugation and lysed with a French 
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Press in phosphate buffered saline with ~1 µg/mL chicken egg white lysozyme, ~1 µg/mL 
bovine pancreatic deoxyribonuclease I, 10 µg/mL leupeptin, 1 µM PMSF, 0.7 µg/mL 
pepstatin.  The lysate was clarified by centrifugation and proteins were purified by Co-NTA 
affinity using Talon resin.  Eluted proteins were further purified by size exclusion 
chromatography, superdex 200, before being snap-frozen in liquid nitrogen and stored at -
80 ˚C until needed.  
 
Expression and purification of GST-CopB. 
The Scc3 binding region of CopB, residues 158-178 based on sequence homology 
with IpaB from Shigella (268),  was expressed as a GST fusion protein from PGEX-4T.  
Proteins were expressed and purified as for His tagged proteins with minor modifications; 
proteins were expressed from BL21 bacteria and purified with Glutathione Sepharose 4B 
(GE Healthcare).  
 
Size exclusion chromatography assays. 
Chaperone, and translocator peptide binding assays were performed by size 
exclusion chromatography, using a 24mL Superdex 200 10/300 GL (GE Healthcare), 
equilibrated in 10mM Tris-HCl pH 7.5, 150mM NaCl, run at 0.5 mL/min, and maintained at 
4˚C.  Equivalent molar concentrations, determined from calculated extinction coefficients, 
of proteins were applied to the size exclusion chromatography column.  Protein complexes 
were incubated for 15 minutes prior to analysis. 
 
Crystallization and preparation of heavy atom derivatives. 
Scc3-CopNΔ84 crystals were grown via vapor diffusion from a reservoir containing 
0.2 M Na/K tartrate and 18-22% PEG 3350.  Crystals were obtained from a 1:1 mixture of 
reservoir and 15mg/mL Scc3-CopN∆84.  KAu(CN)2 derivatives were prepared by adding 
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100mM KAu(CN)2 to the crystal drop to a final concentration of 2mM KAu(CN)2.  After two 
days of incubation derivative crystals were harvested.  Native and derivative crystals were 
cryoprotected with 15% glycerol and flash cooled.  
 
Data collection, structure determination, and analysis. 
Diffraction data were collected from single crystals on stations D and F at LS-CAT 
beam line at the Advanced Photon Source.  Data were indexed, integrated and scaled with 
HKL2000 (295).  Three gold atoms were located and refined using Phenix (296).  The initial 
figure of merit for these sites was 0.46, which improved to 0.70 following density 
modification.  The model was traced with a combination of automated and manual building 
in Phenix and COOT (296,297).  Multiple rounds of refinement were done using Phenix.  
Refinement included simulated annealing, coordinate, individual B-factor, and TLS 
refinement as implemented in Phenix (296).  Non-crystallographic symmetry constraints 
were included in all rounds of positional refinement.  Data collection and refinement 
statistics are given in Table 3-1.  Figures were prepared using Pymol, ClustalW, ESPript, 
the DALI server, the PISA server, and the Consurf server (298-302).  
 
Sequence alignments. 
Sequences used in the Consurf alignments of CopN homologs were chosen to 
represent the sequence diversity within genera shown in Figure 3-2 and included five 
Chlamydial sequences (NP_224529.1, NP_829326.1, YP_515466.1, 84785886, 
332806765, YP_005809291.1), four Shigella sequences (YP_005712038, YP_313363.1, 
YP_001883209.1, YP_406185.1), three Salmonella sequences (1236849, 75349427, 
NP_461818.1), and three Bordetella sequences (NP_880900.1, WP_004568105.1, 
NP_884470.1).  For the two-component gatekeepers, chimeric sequences were generated 
to agree with the spatial orientations in the YopN/TyeA structure (pdb accession code 
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1XL3).  Yersinia YopN sequences used were NP_863522.1, NP_395173.1, and 
NP_052400.1.  Because there is zero sequence diversity in TyeA from species evaluated 
here, I used YP_004210060.1 for all chimeras.  An identical strategy was used for 
Pseudomonas and Vibrio.  Pseudomonas sequences used were NP_250389.1, 
WP_003122865.1, and WP_010794024.1, WP_015648550.1, which were all matched with 
WP_009876220.1.  Vibrio sequences used were NP_798046.1, YP_003285992.1, 
WP_005395115.1, WP_005377238.1, WP_005441804.1, WP_004745560.1, 
WP_005528936.1, which were all matched with WP_005395113.1. 
 
Shigella secretion assay. 
Secretion assays were performed essentially as described (131,303), with minor 
modifications.  Shigella strain M90T was a gift from Marcia Goldberg.  Shigella strain 
ΔmxiC as well as pUC19-mxiC have been previously described, and were gifts from Ariel 
Blocker (131).  The pmxiC-RDR was made by standard molecular biology methods and 
used to transform Shigella strain ΔmxiC.  Strains were grown on tryptic soy broth (TSB) 
plates containing 100µg/mL congo red, with appropriate antibiotics.  Colonies were 
selected and grown overnight in liquid TSB broth at 37 °C and harvested by centrifugation.  
Pellets were resuspended in 5 mLs of fresh liquid medium.  A fraction, ~1:25 final dilution, 
of the resuspended cultures was added to 50 mL TSB cultures and grown to an optical 
density of 1.0 (600 nm).  Cultures were harvested by centrifugation, washed with warm 
media, and resuspended to a final OD600 of 5.0 in PBS + 100 mg/mL Congo Red at 37 °C 
for 10 min and 30 min.  Samples were analyzed by SDS-Page using both coomassie and 
silver staining, as well as western blotting.  Western blotting was done with an α-MxiC 
antibody primary, which was a gift from Ariel Blocker, and goat anti-rabbit secondary 
antibody (LI-COR Biosciences).  Blots were developed with an Odyssey fluorescent 
scanner.  Protein bands were identified from Mass Spectrometry of trypsin-digested bands 
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excised from coomassie-stained gels and was performed by the Vanderbilt University 
Proteomics Core.  
 
 
Results 
 
Structure of Scc3-CopN complex. 
I determined the crystal structure of the Scc3-CopN∆84 complex and refined the 
structure to 2.4 Å (PDB ID 4NRH).  The amino terminal 84 residues of CopN were not 
included in the construct used for crystallization because they are unstructured and 
dispensable for biochemical function (186).  Data collection and structure refinement 
statistics are given in supplemental Table 3-1, and representative electron density is shown 
in Figure 3-1.  Two nearly identical Scc3-CopN∆84 complexes (RMS deviation 0.34 Å for all 
CopN∆84 mainchain atoms and 0.49 Å for all Scc3 mainchain atoms) are present in the 
asymmetric unit.  CopN∆84 forms a long cylindrical structure composed of three 4 or 5-helix 
X-bundle domains (Figure 3-2).  CopN∆84 is structurally similar to other gatekeeper 
proteins, both MxiC from Shigella and the YopN-TyeA complex from Yersinia.  The most 
substantial differences among family members relate to the position of the carboxy-terminal 
domain or subunit (Figure 3-2 and (103,254).  In the Scc3-CopN∆84 complex, this domain is 
translated ~9.5 Å and rotated ~50˚ relative to the YopN-TyeA complex (Figure 3-2).  
Similarly, Scc3 is structurally similar to other translocator chaperones.  The striking result 
from the Scc3-CopN∆84 is the unexpected assembly of the complex and the role of the 
Scc3 amino terminus in binding CopN∆84. 
T3SS chaperones bind the amino terminus of effectors and translocators, and 
class II chaperones (those specific for translocators) use a conserved peptide-in-groove 
binding mode, utilizing the TPR binding groove, in which translocators bind in the concave 
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face of the chaperone (100,101,265,267,268,287,290).  The structure reveals that Scc3 
does not engage CopN∆84 using this conserved binding groove.  Instead, an amino terminal 
extension, referred to here as a gatekeeper-binding region (GBR), forms a relatively flat 
surface, adjacent to the convex side of the TPR and binds across the interdomain interface 
of the last two cross-helix bundle domains of CopN∆84 (Figure 3-2).  The interface formed 
by this interaction results from burial of 980 Å2 of surface area.  The Scc3 side of the 
interface is formed exclusively by residues from the GBR, consistent with separate 
functions of translocator and gatekeeper binding for the TPR and GBR regions of Scc3.  
Despite minimal sequence conservation, the GBR is a conserved feature of other 
translocator chaperones (Figure 3-3, Figure 3-1).  In the homologs from Shigella and 
Pseudomonas it both mediates homo-dimerization and inhibits translocator binding 
(268,291,304).  In the homologs from Yersinia and Pseudomonas crystallization and 
structure determination required removal of the GBR (267,287,290). 
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Table 3-1  Data collection, phasing, and refinement statistics. 	   Au(CN)2 Native 
Data collection   
Space group P21 P21 
Cell dimensions     
    a, b, c (Å) 62.88, 
97.06, 
94.36 
61.57, 
96.18, 
94.47 
     α, β, γ (°) 90.0, 
91.87, 
90.0 
90.0, 
92.27, 
90.0 	     
Wavelength 1.00798 0.97872 
Resolution (Å) 2.8 
(2.85-
2.80)  
2.2 
(2.28-
2.2)  
2.4 
(2.49-
2.40)  
Rsym 8.8% 
(55%) 
6.2 
(55.4) 
5.7 
(34.0) 
I	  /	  σI	   22.5 
(3.25) 
21.1 
(2.4) 
28.4 
(4.46) 
Completeness (%) 100 
(99.7) 
89.7 
(55.4) 
98.0 
(82.2) 
Redundancy 10.9 
(9.6) 
7.3 (4.5) 
7.7(6.3) 
   
Refinement   
Resolution (Å)  50-2.2 
(2.25-
2.2) 
No. reflections  50,339 
(1,807) 
Rwork / Rfree  18.5/22.
2 
No. atoms   
    Protein  7,302 
    Ligand/ion  2 Na+ 
   Water  414 
B-factors   
    Protein  49.8 
    Ligand/ion  51.1 
    Water  48.6 
R.m.s deviations   
    Bond lengths (Å)  0.006 
    Bond angles (°)  0.9 
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Figure 3-1. A Wall-eyed stereo-view of the Scc3-CopN∆84 structure.  2m|Fo|-D|Fc| 
electron density, displayed at 1.5σ is overlaid on the structure.  The map was calculated in 
Phenix (296). The GBR is shown in salmon and CopN is shown in green.  The YopN-like 
domain is shown in dark green and the TyeA like domain is shown in light green. 
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Figure 3-2. Crystal Structure of Scc3-CopN∆84. CopN is colored green, with the YopN 
homology region in dark green and the TyeA homology region in light green. A. A ribbon 
diagram of the Scc3-CopN∆84 structure. Approximate domain boundaries are indicated. 
Scc3, salmon, binds across the domain 2-domain 3 domain interface.  B. A close-up of the 
Scc3-CopN∆84 interface, oriented as in A, with Scc3 shown as a molecular surface.  Scc3 
forms a relatively flat surface that bridges domains 2 and 3 of CopN∆84. C., D. Comparisons 
of CopN and homologs. C. Comparison between MxiC and CopN.  MxiC is colored tan and 
shown with thin helices.  D. Comparison between CopN and the YopN/TyeA complex.  
YopN is tan and TyeA is brown.  YopN and TyeA are and shown with thin helices.  E.   
Overlay of TyeA in orientation shown in D. and when aligned as a rigid body to the carboxy 
terminal 91 residues of CopN (rmsd = 0.4 Å). 
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Figure 3-3.  A., B. Sequence conservation displayed on the CopN∆84 structure (Part 
1).  Residues are colored by conservation (pink is conserved, blue is variable).  A.  Scc3 
interacts with two conserved regions, site 1 and site 2, on CopN.  B.  An expanded view of 
the CopN-Scc3 interface.  For clarity only the GBR region is shown.  The interface is 
primarily composed of hydrophobic residues from Scc3 that surround a conserved arginine 
(R365) on CopN.  C. Sequence conservation within GBR’s is minimal. Scc3 homologs from 
multiple species are aligned based on conservation throughout their sequences, revealing 
that the GBR region is present, but not highly conserved in homologs. Sequences used are 
from C. pneumonia, S flexneri, S. enterica, B. pertussis, Y. enterocolitica, P. aeruginosa, V. 
parahaemolyticus.  Multiple sequences from each genera used in C. were used in A. and 
B. (see methods). 
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The Scc3-CopN interface is conserved in other bacteria. 
Scc3 engages CopN∆84 with residues from the GBR, which bind a contiguous 
surface on CopN∆84.  This surface is formed by two distant patches of sequence 
conservation, region 1 and region 2, and spans the second and third domains of CopN∆84, 
requiring these two domains to be appropriately oriented (Figures 3-1, 3-3, 3-4).  In the 
YopN-TyeA family, the third domain is encoded as a separate protein, such that in these 
homologs one would predict the interdomain interface recognized by the Scc3 homolog to 
be a dimer. 
Residues 16-23 of Scc3 interact principally with region1 of CopN∆84, whereas 
residues 24-43 form a much larger interface in which Scc3 projects a ring of hydrophobic 
side chains toward CopN∆84 to surround a highly conserved arginine on CopN∆84 (Figures 
3-3, 3-4).  This interaction includes three tyrosines, one of which, Y43 is oriented to allow a 
π-cation interaction.  Peripheral to this ring of hydrophobic residues are a collection of inter-
molecular salt bridges (Figure 3-3).  The circumscribed arginine is conserved across 
diverse species, including species with two polypeptide gatekeepers (this residue is an 
arginine in homologs from Shigella, Vibrio, Pseudomonas, Bordetella, and Yersinia and 
glutamine in Salmonella) (Figure 3-3).  Residues on the CopN side of this interface are 
better conserved than those on the GBR, despite the fact that they span two proteins in the 
Yersinia architecture and are on the same protein in the architecture presented here 
(Figure 3-3, 3-5). 
To assess the importance of the two binding regions, I disrupted each interaction 
by mutagenesis.  I made an amino terminal 24 amino acid deletion to Scc3 (Scc3∆24), 
which eliminates the GBR-region one interaction.  I also mutated the central arginine and 
two adjacent residues (G369R, A362R, and R365D) in region 2 of CopN∆84 (CopN∆84-RRD).  
G369, A362, and R365 are buried by Scc3 and likely solvent exposed in unliganded 
CopN∆84.  I introduced charged residues at these sites with the expectation that the solvent 
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exposed charges would not disturb CopN, but would disrupt the CopN∆84-Scc3 complex  
CopN∆84-RRD is stable, as judged by an expression and purification profile similar to 
CopN∆84.  As judged by the inability of Scc3∆24 to bind CopN∆84 and the inability of CopN∆84-
RRD to bind Scc3 (Figure 3-6), both regions are important for Scc3-CopN∆84 complex 
formation. 
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Figure 3-4.  Sequence conservation displayed on the CopN∆84 structure (Part 2).  
Residues are colored by conservation (pink is conserved, blue is variable).  A.  Scc3 
interacts with two conserved regions, site 1 and site 2, on CopN∆84.  B.  An expanded view 
of the CopN-Scc3 interface showing a surface representation of CopN.  For clarity only the 
GBR region is shown.  The interface is primarily composed of hydrophobic residues from 
Scc3 that surround a conserved arginine (R365) on CopN. 
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Figure 3-5.  A gatekeeper sequence alignment reveals that although sequence 
identity is limited, the chaperone binding regions are conserved.  Representative 
sequences from six genera of pathogenic bacteria are shown along with the secondary 
structural elements observed in the CopN structure. As described in the methods, chimeric 
sequences were generated for the two-component gatekeepers by combining YopN and 
TyeA fragments.  The YopN-TyeA domain boundary, the Scc3 interacting sites, and the 
highly conserved arginine are labeled.  Strictly conserved residues are white on a red 
background.  Residues conserved in 5 of the 7 sequences are red on a white background.  
Residues conserved in fewer that 5 sequences are black. 
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Figure 3-6.  CopN-Scc3 binding experiments indicate that both site 1 and site 2 are 
needed for complex formation.  Analytical size exclusion chromatography was used to 
determine the importance of the two sites of interaction in the CopN-Scc3 complex.  A.  
CopN∆84 binds directly to Scc3 as judged by the shift to a single, faster migrating, peak 
when both components are present. Both the change in retention time and the presence of 
both components in the eluted peak, shown in the gel to the right, indicate complex 
formation.  B.  Deletion of the amino terminal 24 amino acids of Scc3 (Scc3∆24) disrupts 
CopN binding as judged the lack of co-migration on the size exclusion chromatography 
column.   C.  Mutation of site 2 on CopN disrupts Scc3 binding as judged by lack of co-
migration on the size exclusion chromatography column.  CopN∆84RRD is mutated at three 
residues in site 1 (G369R, A362R, and R365D).  R365 is the central arginine in site 2. 
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The translocator-binding site in Scc3 is available in the Scc3-CopN complex. 
TPR family proteins are often unfolded when not bound to appropriate ligands and 
are considered to be somewhat flexible proteins (305,306).  Scc3, by contrast appears 
stable with an appropriately organized binding cleft in the absence of ligand.  Structural 
comparison with other class II chaperones, for which structures have been determined in 
complex with translocator-derived peptides, indicates that CopN∆84 binding causes no 
significant reorganization of the translocator-binding site (Figure 3-7).  The Scc3-CopN∆84 
binding mode leaves the translocator-binding site on Scc3 unperturbed and available to 
bind translocators (Figure 3-7).  In support of this observation, the purified Scc3-CopN∆84 
complex is able to directly bind a translocator-derived peptide (presented as residues 158-
177 from CopB fused to GST) and form a CopN∆84-Scc3-CopB158-177 complex as judged by 
size exclusion chromatography (Figure 3-7).  
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Figure 3-7. The Scc3-CopN∆84 complex binds directly to translocators.  A.  An overlay 
of class II T3S chaperones. All structures except the Scc3 structure were determined 
bound to translocator peptides.  For clarity, only the IpaB peptide from Shigella is shown. 
Scc3 is shown in salmon, IpgC (Shigella) in teal, PcrH (Pseudomonas) in green, and SycD 
(Yersinia) in blue.  The peptide-binding site is conserved and open in Scc3.  B. CopN-Scc3 
complex directly binds to the CopB translocator. Top: size exclusion chromatography 
traces reveal that the ternary complex is tight enough to survive size exclusion 
chromatography.  Bottom:  SDS PAGE confirming complex formation. 
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Disruption of the Scc3-CopN interface alters secretion in Shigella. 
To determine the importance of the gatekeeper-chaperone interaction during T3S, I 
disrupted the homologous gatekeeper-translocator chaperone interface in Shigella.  
Shigella, unlike Chlamydia, are genetically tractable allowing disruption of the endogenous 
mxiC gene (the copN homolog) and rescue with a plasmid expressing mutant or wild-type 
MxiC.  This is a well-established strategy that has been used to study other MxiC mutants 
(131,132).  The CopN and Scc3 homologs in Shigella, MxiC and IpgC, form a complex that 
includes the T3SS ATPase (132).  The Scc3-CopN∆84 structure was disrupted by mutation 
of G369R, A362R, and R365D on CopN (Figure 3-6), supporting the idea that the 
homologous mutations would disrupt IpgC-MxiC interface.  I expressed the 
E331R/R334D/I338R MxiC mutant (MxiC-RDR) from a plasmid in a previously described 
mxiC null Shigella strain (131) and compared secretion profiles following Congo Red 
induction.  MxiC-RDR is deficient in secretion of the translocators IpaB, IpaC, and IpaD, but 
efficiently secretes IpaA, an effector, and secretes elevated levels of the effectors OspC1-3 
and IpgB (Figure 3-8).  IpaA is not secreted efficiently if wild type MxiC is present, but is 
secreted earlier and in greater quantities ∆MxiC or MxiC-RDR strains (Figure 3-8).  The 
secretion profile of MxiC-RDR closely mimics that of the ∆MxiC strain (Figure 3-8) 
highlighting the importance of gatekeeper-translocator chaperone complexes in 
translocator secretion.  Similar to CopN, MxiC is both the gatekeeper and a T3S substrate 
(130,131,196).  To verify that the mutations to MxiC did not destabilize MxiC, or otherwise 
prevent recognition and secretion of MxiC by the T3SS, I evaluated the secretion of MxiC-
RDR (Figure 3-8).  MxiC-RDR is secreted in a similar manner to MxiC, indicating that the 
mutations do not disrupt its ability to interact with the T3SS, yet is unable to direct 
translocators for secretion, and is unable to prevent inappropriately early secretion of IpaA, 
OspC1-3, and IpgB. 
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Figure 3-8.  The gatekeeper-chaperone complex is needed for efficient translocator 
secretion.  A.  T3S was induced from wild type and mxiC mutant Shigella strains.  M90T is 
a wild type strain. ∆mxiC is M90T derived, with mxiC deleted (131).   EV: empty vector.  
Strains were complemented with mxiC, mxiC mutant (RDR), or empty vector (EV). Proteins 
were visualized by silver staining and identified by MS.  IpaA, OspCs, and IpgB are 
effectors.  IpaB, IpaC, and IpaD are translocators.  Bottom: anti-MxiC blot of the same 
samples indicates that MxiC and MxiC-RDR are secreted normally.  B.  A secretion time 
course.  The experiment shown in A. was repeated and samples taken a 10, 15, 30, and 
60 minutes post induction.  IpaA, an effector, is not secreted efficiently until ~30 minutes in 
the presence of MxiC, but in the absence of MxiC or in the presence of only MxiC-RDR it is 
secreted at ~10 minutes post induction. 
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Discussion 
 
In this study I have presented the structure of CopN∆84 bound to Scc3.  This 
structure provides the first description of a novel interaction for translocator-chaperones, 
which involves an amino-terminal extension, termed the GBR, binding across the YopN-
TyeA-like domain interface in CopN∆84.  The translocator-chaperone-gatekeeper interaction 
involves a conserved arginine from the gatekeeper and the amino terminal GBR from the 
chaperone.  Despite the high conservation of the gatekeeper arginine, there is limited 
sequence conservation within the GBR.  Despite this lack of sequence conservation within 
the chaperone, the presence of a GBR in class II chaperones appears to be conserved 
(Figure 3-3).  Scc3’s GBR is ~20 amino acids longer than others, implying that the 
extensive interactions made to the YopN-like domain are likely unique to the Scc3-CopN∆84 
complex.  Although the unique α1 helix of Scc3 (amino acids 2-15) does not contact CopN, 
α1 does orient the α1- α2 loop, which contacts CopN.  In organisms with shorter GBRs, 
other T3S apparatus components likely contribute to organizing this interface.  This 
appears to be the case in Salmonella, where the gatekeeper interacts with the translocator-
chaperone when it is bound to either translocator, but not to the empty chaperone (127).  In 
Shigella and Pseudomonas, the translocator-chaperones are known to homodimerize 
using the amino terminus, and translocator binding is necessary to disrupt this dimer 
(291,304).  Although the monomeric chaperone is able to bind translocators, the data 
suggest a role for the chaperone amino terminus distinct from the role in homodimerization, 
namely a role in gatekeeper binding.  Consistent with previous reports (291,304), I suggest 
that disruption of chaperone homodimers, by translocator binding, likely occurs prior to 
chaperone-gatekeeper complex formation. 
The binding mode observed in this structure leaves the canonical translocator-
binding groove free and available to bind translocators.  The Scc3-CopN∆84 complex binds 
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directly to CopB (Figure 3-7), a Chlamydial translocator, thus establishing a physical link 
between the gatekeeper and a translocator.  By physically linking gatekeepers and 
translocators, the temporal order of secretion events (gatekeepers, followed by 
translocators, and then effectors) is assured.  The unusual CopN-Scc3 interface and 
relatively small buried-surface area (980 Å2) are consistent with the physiological role of 
this complex, in that the gatekeeper-translocator chaperone must assemble and 
disassemble each cycle of translocator secretion. 
In Chlamydia the CopN-Scc3 interaction can be formed with purified proteins, 
suggestion that it is stronger than in homologous systems, likely because the GBR is 
longer and complex formation is not prevented by chaperone homodimerization.  The 
precise advantage this affords Chlamydia is unclear, but T3S activation may represent an 
early “committed step” for Chlamydia infection.  As obligate intracellular pathogens, the 
need for Chlamydia to enter their host subsequent to T3S activation seems absolute.  
Chlamydia are dependent on their hosts for ATP (189) and therefore a T3S event that 
doesn’t result in entry is likely fatal for the bacterium.  Consistent with this idea, Chlamydia 
also express a second translocator chaperone, Scc2, which is expressed during late 
stages of infection, after invasion, and does not bind CopN (234,235). 
Mutations shown to disrupt the CopN-Scc3 complex were evaluated in the MxiC-
IpgC complex.  The highly conserved central arginine and two additional charged residues, 
located at positions homologous to the sites mutated in CopN, were mutated 
(E331R/R334D/I338R) on a MxiC expressing plasmid and used to complement a mxiC 
deletion strain.  This mutant MxiC (MxiC-RDR) was expressed and secreted normally, 
indicating that the mutations did not significantly disrupt MxiC.  Strains harboring MxiC-
RDR, however, mimicked deletion strains and were both deficient in translocator secretion 
and secreted elevated levels of effectors, resulting in significant effector secretion at early 
time points, prior to translocator secretion.  These results support the conclusion that a key 
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function of MxiC during secretion is to scaffold translocators and that the MxiC-IpgC 
complex is needed for this function.  This arrangement, in which assembly of a gatekeeper-
chaperone-translocator complex is needed to both promote translocator secretion and to 
prevent effector secretion indicates that the relevant “plug” that prevents premature effector 
secretion is the gatekeeper-chaperone-translocator complex.  Consistent with this 
interpretation, disruption of IpaB (a Shigella translocator) or MxiC (the gatekeeper) both 
cause constitutive effector secretion (131). 
Collectively, these results support a new mechanism for the translocator-effector 
hierarchy, outlined in Figure 3-9.  I suggest that the translocators are recruited to the T3S 
pore as a molecular complex including the gatekeeper, translocator-chaperone, and 
translocator.  The entire complex is needed both to promote translocator secretion and to 
prevent effector secretion.  A triggering event from the tip of the T3S needle is known to 
induce gatekeeper release (131), which through the molecular complex described above is 
directly linked to translocator secretion.  Secretion of the gatekeeper and translocator then 
allows effector secretion through a gatekeeper independent mechanism, similar to the 
efficient effector secretion seen in gatekeeper mutants. 
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Figure 3-9.  A minimal cartoon model for three steps of T3S, highlighting a role for 
the gatekeeper-chaperone complex in translocator secretion.  Before host 
engagement gatekeeper-chaperone-translocator complexes are bound to the apparatus 
and prevent secretion of effectors. Upon binding of the apparatus to target membranes the, 
gatekeeper and pore forming translocators are secreted.  The pore forming translocators 
assemble within the target membrane to form the translocon.  After translocator and 
gatekeeper secretion, the apparatus is able to efficiently secrete effectors, which are 
secreted through the translocon directly into the host cytosol. 
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CHAPTER IV 
 
CHLAMYDIA PNEUMONIAE GATEKEEPER PROTEIN, COPN, SEQUESTERS αβ-
TUBULIN USING A CONSERVED BASIC FACE.	  
 
Introduction 
 
 Chlamydiae species are obligate intracellular bacteria that utilize a biphasic life 
cycle consisting of metabolically inactive elementary bodies (EBs) and metabolically active 
reticulate bodies (RBs) (191).  Infection involves attachment and cellular uptake of EBs and 
subsequent differentiation into RBs.  The RBs remain in endosome-derived membrane 
vacuoles termed ‘inclusions,’ which migrate to the microtubule-organizing center (MTOC) in 
a dynein and microtubule (MT) dependent process (192,193,243).  After multiple rounds of 
bacterial cell division an unknown cue causes the RBs to re-differentiate into infectious EBs 
and spread to neighboring cells (191).  As with many other gram-negative bacteria, 
Chlamydia use a type three secretion system (T3SS) and T3SS effectors to subvert host 
defenses and reprogram cell processes (188,196,244).  A prominent target of these 
effectors is the host’s MT cytoskeleton (185,192,193,243).  Alteration of the host MT 
cytoskeleton is required for proper localization of inclusions to the MTOC and association 
of inclusions with centromeres (307).  Additionally, Chlamydia infection disrupts the cell 
cycle, resulting in delayed cytokinesis and failure to properly segregate sister 
chromosomes (185,192,253).  One effector known to target the MT cytoskeleton is CopN, 
which is known to bind tubulin, inhibit MT formation, prevent metaphase plate formation, 
destroy microtubule networks, and cause mitotic arrest (185,186,196).  CopN is also a 
T3SS gatekeeper protein that directs the switch between translocator and effector 
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secretion (196) (and Archuleta, submitted), raising the question of how effector function is 
encoded in the presence of other functional constraints. 
Type Three Secretion Systems (T3SS) are conserved bacterial protein delivery 
machines used by many pathogenic Gram-negative bacteria to deliver a diverse group of 
protein molecules, termed effectors, into cells (245,281-283).  The type three secretion 
(T3S) apparatus is a conserved molecular machine that forms a protein-conducting 
channel from the bacterial cytosol to the target cell cytosol (Figure 4-1).  Major structural 
components of the T3SS include: a cytosolic-ring complex that includes the ATPase that 
catalyzes protein unfolding and secretion; a basal-body that forms a pore across both the 
inner and outer bacterial membranes; a needle complex that extends from the basal-body 
to the host cell; and a translocon pore formed in the target cell membrane 
(110,284,286,308). 
T3S is regulated in numerous ways, including regulation at the levels of 
transcription, assembly, and activation (265,285,309,310).  A regulatory failsafe, which is 
conserved across species, involves the gatekeeper proteins, which block the secretion 
pore until T3S is activated (127,133,181,182).  External cues initiate secretion, at which 
time gatekeepers are secreted and the T3SS becomes active (103,130-132,181,311,312).  
The exact mechanism by which an external signal is received by the gatekeeper is 
unknown, but it is known to involve a conformational change in the “Tip translocator” (a 
translocator that resides at the extracellular tip of the T3S needle), which is transmitted 
through the inner-rod components of the needle (131,313-316).  I have recently shown that 
the Chlamydial gatekeeper, CopN, is also a molecular scaffold that recruits proteins to the 
T3SS (submitted).  These discrete molecular functions are encoded in a ~400 amino acid 
protein.  Gatekeepers interact with translocator chaperones, the C-ring of the T3S, and 
inner-rod components from the T3S needle (127,130-132,186,234,235).  Despite the 
conservation needed to maintain these functions, gatekeepers have acquired additional 
	   85	  
effector functions (184-186).  The best studied of these is the microtubule destabilizing 
function of CopN from Chlamydia pneumoniae. 
CopN is both the T3SS gatekeeper and a secreted effector protein that causes 
cell-cycle arrest, binds αβ tubulin, and inhibits microtubule formation 
(133,185,196,235)(Archuleta, submitted).  I have suggested that CopN disrupts 
microtubules by sequestering αβ tubulin, a mechanism it shares with stathmin, a eukaryotic 
tubulin binding protein (225,236-239).  Unlike stathmin, CopN is a folded protein with a 
defined and well-ordered tertiary structure (Archuleta, submitted).  Further, CopN lacks 
identifiable tubulin-binding sequences, which are conserved among even highly divergent 
stathmins, and lacks any detectable sequence identity with stathmins (186,263).  CopN 
and stathmin lack sequence identity or structural similarity, yet both inhibit MT assembly by 
sequestering free αβ tubulin.  Further, CopN and stathmin bind overlapping sites on tubulin 
as evidenced by competition between the two for tubulin binding sites (186).  These data 
suggest that Chlamydia have encoded stathmin-like functions on a structurally unrelated 
protein. 
 
 
Methods 
 
Purification of His tagged proteins. 
CopN∆84 and Scc3, from C. pneumoniae AR39, were amplified and cloned into 
pET28 with an amino-terminal hexa-histadine tag.  CopN∆84 is an amino terminal 84 amino 
acid deletion of CopN (186).  All CopN variants were made in pET28 using PCR based 
mutagenesis and verified by sequencing.  Proteins were expressed in BL21 (DE3) bacteria 
grown in Luria Broth at 37 ˚C.  Bacteria at an optical density (at 600 nm) of ~0.6 were 
induced at 20˚C with 0.1mM isopropyl β-D-thiogalactopyranoside, and grown for ~12 
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hours.  Cultures were harvested by centrifugation and lysed with a French Press in 
phosphate buffered saline with ~1 µg/mL chicken egg white lysozyme, ~1 µg/mL bovine 
pancreatic deoxyribonuclease I, 10 µg/mL leupeptin, 1µM PMSF, 0.7 µg/mL pepstatin.  The 
lysate was clarified by centrifugation and proteins were purified by Co-NTA affinity using 
Talon resin.  TOG1 domain construct 1-272 was overexpressed in E. coli and purified by 
Ni-affinity and size exclusion chromatography as described previously (317).  All eluted 
proteins were further purified by size exclusion chromatography, superdex 200, before 
being snap-frozen in liquid nitrogen and stored at -80 ˚C until needed. 
 
Tubulin purification. 
Fresh bovine brains were obtained from a local slaughterhouse (C and F Meat 
Company, College Grove, TN) and tubulin was prepared as described (255), with the only 
modifications being that 600g of bovine brains rather than 1 Kg of porcine brains were 
used (buffer volumes were adjusted accordingly) and that the rotors used were a JA-10, Ti-
45, and Ti-70.1 rather than SLA 1500, Ti-45, and TLA 100.4 (rotor velocities were adjusted 
to achieve appropriate g forces).  Tubulin was snap-frozen in BRB80 buffer (80mM PIPES, 
1mM MgCl2, 1mM EGTA, pH 6.8) in liquid nitrogen and stored at -80 C until needed. 
 
Size exclusion chromatography assays. 
CopN homologs, Scc3, Tubulin, and TOG1 binding assays were performed by size 
exclusion chromatography, using a 24mL Superdex 200 10/300 GL (GE Healthcare), 
equilibrated in 10mM Tris-HCl pH 7.5, 150mM NaCl, run at 0.5 mL/min, and maintained at 
4˚C. Equivalent molar concentrations, determined from calculated extinction coefficients, of 
proteins were applied to the size exclusion chromatography column.  Protein complexes 
were incubated for 15 minutes prior to analysis. 
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Tubulin turbidity assays. 
Turbidity assays were performed in triplicate in a BioTek Synergy 4 plate reader in 
96 well plates.  Each assay well included 150µg of tubulin, 3mM GTP, 80mM PIPES, 2mM 
MgCl2, 0.5mM EGTA, and 30% glycerol in 300µL total volume.  Plates were setup on ice, 
mixed, and transferred to an incubated plate reader maintained at 37˚C, absorbance at 
340nm was measured at 45sec intervals, and the plates were shaken for 5sec before each 
measurement.  Data presented are the average of three replicate wells. 
 
Microtubule assembly assays. 
To assay Microtubule assembly in the absence or presence of CopNΔ84, we used 
microtubule ‘spindown experiments’.  Yeast αβ tubulin (3μM) was polymerized without or 
with CopNΔ84 (9μM) in assembly buffer (100mM PIPES pH 6.9, 2mM MgSO4, 1mM 
EGTA, 10% glycerol, 1mM  GTP) for 40 minutes at 30˚C.  The Assembly reactions were 
cross‐linked by diluting 10‐fold into assembly buffer containing 1% glutaraldehyde and 
incubating 3 minutes at 30 ˚C.  Cross-linking was then quenched by 5-fold dilution into 
assembly buffer containing 25mM Tris pH 6.8. 50μL of the quenched, cross-linked 
reactions was applied to the top of a glycerol cushion (20% glycerol in BRB80) and spun 
through the cushion at 22,579xg for 45 minutes at 20˚C (rotor JS13.1) onto poly‐lysine 
coated coverslips.  Coverslips were fixed using cold (20˚C ) methanol for 3 minutes, 
blocked with 1mg/ml BSA and stained using FITC-DM1α (Sigma Aldrich).  Fluorescence 
Imaging was performed using an Olympus IX81 Inverted microscope with a 60X objective. 
 
Molecular Modeling. 
The molecular models shown in Figure 4-1 were constructed using the program 
Modeller (318) as implemented in Chimera (319) with the C. pneumoniae CopN structure 
serving as a template for the C. trachomatis and C. psittaci sequences. 
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Results 
 
CopN contains a large, conserved, basic face. 
The recent crystal structure of CopN bound to Scc3, a chaperone for T3S 
translocators, has aided efforts to identify the tubulin-binding site on CopN.  As described 
in Chapter III, residues 85-399 of CopN form an elongated helical-cross-bundle structure 
that is similar to other T3S gatekeepers without any evident tubulin binding appendages.  
Previous work has indicated that CopN residues 1-84 are not required for tubulin binding, 
indicating that tubulin binding is encoded by residues resolved in the recently reported 
structure (186).  I have analyzed the CopN structure (pdb code 4NRH) and identified an 
electro-positive, or basic, surface that I show below includes the binding site for tubulin 
(Figure 4-1). 
Although the amino acid composition of CopN is not remarkable (9.7% Arg+Lys 
and 13.6% Asp+Glu for the construct used in crystallization), the distribution of charged 
residues results in one face of CopN being largely basic, while another face is largely 
acidic (Figure 4-1).  Because tubulin is known to use an acidic patch to bind both stathmin 
and tog domains (239,317), I reasoned that the large basic patch might be functionally 
important and assessed its conservation within other Chlamydial CopN proteins.  Using a 
combination of molecular modeling and sequence alignments, I found that the basic region 
is indeed conserved, Figure 4-2.  CopN from C. trachomatis is less effective than CopN 
from either C. pneumoniae or C. psittaci (186), at inhibiting tubulin polymerization (186) 
and consistent with this observation the basic patch on CopN from C. trachomatis is less 
basic, with three basic residues replaced by polar, non-basic, residues (K242N, R250S, 
R268S).  Two of these residues (K242 and R250) map to the center of the basic region, 
while the third (R268) is adjacent to the Scc3 binding site, Figures 4-1 and 4-2. 
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Figure 4-1. The basic face of CopN is conserved between C. pneumoniae and C. 
psittaci.  The above electrostatic calculated from the structure of C. pneuomoniae CopN 
and models of CopNs from and C. psittaci and C. trachomatis.   The models were 
produced using the C. pneuomoniae CopN structure and the program Modeller.  These 
electrostatic renderings of each of the CopN homologs show a conserved basic face. 
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Tubulin binds CopN’s basic face. 
The CopN-Scc3 structure shows the Scc3 binding site to be distal to these 
mutations, toward the carboxy-terminal end of CopN (Figure 4-2 A).  Scc3, however, binds 
within the basic face of CopN (Figure 4-2 A,B).  I reasoned that tubulin and Scc3 may bind 
overlapping sites on CopN and assessed competition between Scc3 and tubulin for a 
binding site on CopN by size exclusion chromatography.  As shown in Figure 4-2 C, Scc3 
and tubulin both bind CopN and shift the retention time toward a larger complex, a ternary 
complex, however, cannot be formed, consistent with a shared binding site on CopN for 
Scc3 and tubulin.  Because CopN potently inhibits tubulin polymerization as assayed by 
light scattering (186) (and Chapter II), I evaluated Scc3 for its ability to restore tubulin 
polymerization.  I added stochiometric quantities of Scc3 to a tubulin polymerization 
experiment, and as expected from the size exclusion chromatography data, Scc3 restores 
tubulin polymerization (Figure 4-2 D), likely by binding CopN and preventing CopN from 
binding tubulin. 
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Figure 4-2. Tubulin and Scc3 compete for binding on CopN’s basic face.  A. A ribbon 
diagram of the Scc3-CopN∆84, CopN in blue and Scc3 in salmon, structure with residues 
K242, R250, and R268 highlighted in red.  This diagram notes Scc3 binding below the 
highlighted basic residues.  B. Scc3 binds the distal basic end of CopN.  C. Tubulin and 
Scc3 compete for binding to CopN.  The size exclusion chromatography traces reveal that 
the no ternary complex forms when Scc3, tubulin, and CopN are run together, suggesting 
tubulin and Scc3 compete for binding to CopN.  D. Tubulin polymerization experiment.  
Curves represent extent of tubulin polymerization as monitored by light scattering.   
Controls of Taxol and Vinblastine indicate the dynamic range of the assay.  The “Tubulin” 
curve indicates the expected time course and extent of polymerization for tubulin alone 
under these conditions (6 µM tubulin, 30% glycerol). CopN inhibits tubulin polymerization, 
however, addition of Scc3 recovers the tubulin polymerization. 
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CopN competes with Tog1 for a binding site on tubulin. 
 
Tubulin contains a compatible acidic face, Figure 4-3 B, that I reasoned might bind 
the basic face of CopN.  Using a similar competition binding strategy to that above, I have 
shown that while CopN and Tog1 from Stu2p both bind tubulin, as assessed by size 
exclusion chromatography, a ternary complex cannot be formed (Figure 4-3 A).  Indicating 
that they bind overlapping sites, or binding of one induces a conformational change that 
precludes binding of the other.  Complementary binding experiments have already 
established that CopN and stathmin compete for a similar site on tubulin (186) (and 
Chapter II), and the stathmin-tubulin and Tog1-tubulin have been determined and both 
effectors do indeed target the same acidic face of tubulin (Figure 4-3 B).  These data, 
therefore, support the hypothesis that a single acidic patch on tubulin is the binding site for 
CopN, tog domains, and stathmin. 
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Figure 4-3. CopN competes with Tog1 for a binding site on tubulin’s acidic face.  A. 
CopN and TOG1 domain compete for binding to tubulin. The size exclusion 
chromatography traces reveal that the no ternary complex forms when TOG1, tubulin, and 
CopN are run together, suggesting TOG1 and CopN compete for binding to tubulin.  B. An 
electrostatic rendering model of one αβ heterodimer of tubulin.  The model reveals the 
acidic face of tubulin responsible to CopN and TOG1 binding (317). 
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Mutation of CopN’s basic face disrupts function. 
 
The above results lead us to suggest that the basic face on CopN binds the acidic 
patch on tubulin.  As an alternative test of this hypothesis, I have evaluated mutations 
designed to disrupt the basic region, but to otherwise not destabilize CopN.  Based on the 
crystal structure I designed K242E/K249E/R250E in which three conserved basic residues 
are replaced with glutamate.  This protein, ∆84CopN-T is stable as judged by its size 
exclusion chromatography and by its ability to bind Scc3, but is unable to bind tubulin 
(Figure 4-5 A). 
As a final test, I evaluated ∆84CopN-T for its ability to inhibit MT formation in an 
MT spindown assay.  In this tubulin polymerization assay, fluorescently labeled tubulin was 
incubated with ∆84CopN-T or ∆84CopN and polymerization was initiated by dilution into 
10% glycerol containing buffer.  Samples were then cross-linked and spun onto 
microscope slides and MT were viewed in a fluorescent microscope.  Under these 
conditions 9μM ∆84CopN completely abolished MT formation, while an equivalent 
concentration of ∆84CopN-T had no discernable effect (Figure 4-5 B).  The above 
experiments were preformed by collaborators from the laboratory of Dr. Luke Rice. 
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Figure 4-4. Mutation of CopN’s basic face disrupts function.  A. The CopN mutant, 
CopNΔ84 T, does not bind tubulin.  The CopNΔ84T with mutations made at K242E, 
K249E, and R250E does not bind tubulin, but this tubulin-binding mutant retains the ability 
to bind Scc3.  B. CopNΔ84 T has no effect on polymerized tubulin.  The three panels show 
the effects of CopN on polymerized microtubules: the upper left panel is a tubulin alone 
control; the upper right panel contains tubulin and CopNΔ84 from C. pneumoniae; and the 
bottom panel contains tubulin and CopNΔ84 T from C. pneumoniae.  As compared to the 
control, CopNΔ84 from C. pneumoniae causes disassembly of the microtubule network, 
upper right panel. 
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Discussion 
 
CopN is a key component of the Chlamydial T3SS, functioning as a molecular 
scaffold that likely influences the secretion hierarchy (Chapter III), as a gatekeeper that 
regulates secretion (Chapter III), and as a secreted effector (Chapter II).  Encoding these 
functions on a relatively small protein surface has been accomplished by evolving a tubulin 
binding site, which appears to be a unique feature of Chlamydial gatekeepers, adjacent to 
the translocator chaperone binding site, which appears to be common across multiple 
species (Chapter III).  While Scc3 and Tubulin bind competitively to their respective binding 
sites, supporting the idea that the binding sites overlap, this is not likely physiologically 
important because Scc3 family chaperones are not secreted and tubulin is only present in 
the host.  The ability of one surface to bind two different and unrelated proteins highlights 
the structural and functional diversity present even in small proteins. 
Although CopN bears no structural similarities to other tubulin binding proteins, it 
appears to target a similar binding site on tubulin.  CopN, Stathmin, Tog domains, and 
Kinesin all appear to bind the same acidic patch on tubulin (236,237,239,317,320).  In this 
regard, CopN mimics cellular tubulin binding proteins.  This mimicry is quite remarkable in 
that CopN disrupts MT assembly, Tog domains typically promote MT assembly, and 
Kinesin moves along assembled MTs (186,220,321).  The different outcomes of binding to 
this site cannot currently be reconciled, but support the notion that tubulin assembly can be 
exquisitely regulated by effector proteins.   
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
 
Chlamydiae species are obligate intracellular pathogens that utilize a type a T3SS 
to deliver effector proteins and manipulate host cell processes.  T3SSs are composed of 
conserved components; cytosolic components, a needle complex, which forms the conduit 
for secreted proteins, and translocators, which form the pore in the target cell.  While the 
components that form the T3SS are conserved, the effectors are diverse.  Despite T3SS 
machinery conservation, these proteins can acquire additional functions while maintaining 
their roles in the T3SS.  One such multifunctional protein, CopN, is both T3SS effector and 
a regulator of secretion (133,185,196,235).  CopN is a member of a family of T3SS 
regulators known as “gatekeeper” proteins that control effector secretion in other 
organisms.  In its effector role, CopN binds free αβ tubulin and inhibits microtubule 
polymerization. 
Chapter II of this document describes that CopN directly binds αβ tubulin and 
inhibits tubulin polymerization into MTs.  In this chapter, size exclusion chromatography 
analysis shows CopN binds directly to the class II chaperone, Scc3.  Class II chaperones 
are monomeric all a helical tetricopeptide (TPR) proteins (266-268).  Scc3 is similar to 
SycD from Yersinia and IpgC from Shigella, both of which are class II chaperones with a 
TPR fold that binds translocators (266-268).  Previous studies show that expression of 
CopN in eukaryotic cells results in severe alterations in the MT network, including 
destruction of mitotic spindles (185).  In Chapter II, I show that destruction of MTs is 
caused by CopN directly binding to αβ tubulin.  CopN inhibits MT formation, but does not 
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bind or depolymerize existing MTs.  These data suggest that its mechanism of action is 
through binding of αβ tubulin in a sequestration manner like that of the eukaryotic tubulin 
binding protein, stathmin (225,236-239).  
In Chapter III, I presented the crystal structure of the Scc3-CopN∆84, which reveals 
a CopN-Scc3-translocator scaffold.  Experiments in Shigella show that this scaffold is 
necessary for the ordered secretion of translocators before effectors.  These data show 
CopN∆84 is structurally similar to other gatekeeper proteins, both MxiC from Shigella and 
the YopN-TyeA complex from Yersinia, and Scc3 is structurally similar to other translocator 
chaperones.  The striking result from the Scc3-CopN∆84 is the unexpected assembly of the 
complex and the role of the Scc3 amino terminus in binding CopN∆84.  The Scc3-CopN∆84 
complex binds directly to the Chlamydial translocator, CopB, establishing a physical link 
between the gatekeeper and translocator.  The mutations shown to disrupt the CopN-Scc3 
complex were evaluated in the MxiC-IpgC complex in Shigella, and these data indicated 
that strains containing the mutations mimicked a deletion strain and were both deficient in 
translocator secretion and secreted elevated levels of effectors, resulting in significant 
effector secretion at early time points, prior to translocator secretion. 
Finally in Chapter IV, I present data that indicates CopN basic face binds tubulin’s 
acidic face.  Structural studies of CopN revealed a basic face in which Scc3 binds to the 
distal end.  This basic face is conserved between CopN homologs.  In addition to sequence 
conservation, binding assays between Scc3 and tubulin show a ternary complex cannot be 
formed with CopN, Scc3, and tubulin.  Also, turbidity assays reveal CopN no longer has an 
inhibitory effect on tubulin polymerization when Scc3 is added to the same experiment.  
Further mutagenesis to conserved residues on CopN show a loss of tubulin binding via 
size exclusion chromatography and MT spindown assays.  
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Future Directions 
 
Determine a high-resolution crystallographic structure of the CopN-tubulin complex. 
A crystallographic structure of the CopN + tubulin complex will give information 
regarding how CopN engages and sequesters tubulin.  Previous studies show which 
residues are required for tubulin binding, however, it would be interesting to find other 
residues involved in tubulin sequestration.  In my attempts to crystallize the CopN-tubulin 
complex has resulted in small unusable crystals for data collection (Figure 5-1).  These 
crystals will either need to be optimized using CopNΔ84+bovine tubulin, or, a better 
strategy, using a CopNΔ84 + unpolymerizable yeast tubulin (317).  In addition, this 
structure will aid in future studies done to move forward with a drug discovery screen.  The 
structure will allow for us to see how a drug might disrupt the binding of CopN to tubulin. 
 
Determine a high-resolution crystallographic structure of the CopN-Scc3-CopB complex. 
Along with optimizing the co-crystals of CopN + tubulin, optimization of the CopN-
Scc3-CopB complex crystals should also occur.  The crystals that I have currently obtained 
diffract to ~ 3-3.5Å.  Further optimization is required because although these crystals are 
improved in resolution relative to the initial crystals, diffraction is highly mosaic and 
anisotropic.  These problems prevent data processing.  In addition to determining the 
structure of the CopN-Scc3-CopB complex, we would like to determine potential 
therapeutics for inhibiting the interaction between the gatekeeper, CopN, and the 
translocator scaffold.  These assays would be accomplished via a high throughput 
screening assay. 
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Determine the role and location of CopN during Chlamydial infection. 
Finally, a long-term goal is to determine CopN’s role in infection.  This body of work 
identifies CopN as an effector that sequesters αβ tubulin in the eukaryotic cell, but it is still 
unclear why and when CopN achieves its purpose.  For example, is CopN’s purpose to 
shut down cell cycle regulation at a particular time during infection?  Where is CopN 
localized in the eukaryotic host?  These are difficult questions to answer given the evasive 
life cycle of Chlamydia, however, and will be answered require genetic tools. 
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Figure 5-1. Crystallization of the CopN+tubulin complex.  The above panels are 
examples of micro-crystals I was able to grow.  These crystals are too small for data 
acquisition.  These crystals must be grown larger in order to collect diffraction data. 
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Figure 5-2. Crystallization of the tertiary complex between CopN+Scc3+CopB.  The 
above panels are examples of current crystal form of the CopN+Scc3+CopB complex.  
These crystals require further optimization for better diffraction quality data.  I have been 
able to able to optimize these crystals, which currently diffract to ~ 3-3.5Å.  However, I am 
unable to index the diffraction data, suggesting the crystals are not single. 
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